Blog Archive, 2012 – 2020

2020 • 2019 • 2018 • 2017 • 2016 • 2015 • 2014 • 2013 • 2012

2020 (2)

• 31.08. | Very Important Joint Announcement from HepCBC and Pacific Hep C Network
• 24.07. | One-Step Hepatitis C Testing Now in BC!

2019 (38)

• 13.11. | Seniors Fair at the Aboriginal Mother Centre, Vancouver – Nov. 7, 2019
• 13.11. | BC’s Nurse Practitioners Can Now Prescribe Treatment for Hepatitis C
• 12.11. | 2017 Outreach Visit to NW BC
• 29.10. | Prison Colour Book Contest Winning Entries Become Posters
• 05.06. | FREE June 11 Webinar on Indigenous Prison-Community Partnership Study
• 05.06. | ASSESSING RISKS to the LIVES of Canada’s INDIGENOUS WOMEN
• 05.06. | FEDERAL PRISONS in BC will be VISITED by HepCBC TEAM June 10-14, 2019
• 05.06. | BLUEPRINT for ELIMINATING HEPATITIS C in CANADA
• 05.06. | CONTAMINATED BLOOD SCANDAL HEARINGS finally being held in UK
• 05.06. | FDA approves first treatment for all HCV genotypes in CHILDREN (USA)
• 05.06. | Consultation Tool for Hepatitis B Decision-Making – Free Application from CCO
• 05.06. | FREE Seminar in HCV Elimination among Men Who Have Sex with Men (MSM)
• 05.06. | FREE Seminar in HCV Elimination among Persons Who Inject Drugs (PWID)
• 22.03. | BC PharmaCare lists Maviret™ treatment for HCV
• 23.02. | The Week in Review: Jan. 25, 2019 – Feb. 22, 2019
• 22.02. | MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario
• 22.02. | Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV)
• 22.02. | No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring Protocols?
• 16.02. | In Memoriam: Anita York
• 25.01. | The Week in Review: Jan. 18, 2019 – Jan. 25, 2019
• 24.01. | Using Nurse-led HCV Care Model in Prisons in AUSTRALIA
• 24.01. | Using Telemedicine HCV Care Model in Prisons in SPAIN
• 24.01. | Saturday in Surrey! Visit HepCBC booth at January 26th Surrey Health Expo
• 24.01. | Free CME-certified WEBINARS on Fatty Liver Disease Jan. 29-31, 2019
• 24.01. | New Study Shows Potential Benefits of Screening All New Cancer Patients for Hepatitis
• 18.01. | The Week in Review: Jan 11, 2019 – Jan 18, 2019
• 18.01. | Photos of January 10, 2019 HepCBC Community Dinner in Memory of Phil Wilkin at Our Place
• 18.01. | Invitation to HepCBC Info Booth at Sat. Jan. 26th SURREY HEALTH EXPO!
• 18.01. | Egypt Shares its Hepatitis Elimination Successes with its Neighbours in Africa
• 18.01. | Mapping BC’s Core Hepatitis C Areas Improves Targeted Treatment
• 11.01. | The Week in Review: Jan 4, 2019 – Jan 11, 2019
• 11.01. | Winners of HepCBC’s November and December, 2019 Colouring Book Contest Announced
• 11.01. | Dramatic Series, UNSPEAKABLE about Canada’s Tainted Blood Scandal
• 09.01. | B.C. removes prescription drug deductibles for low-income residents
• 04.01. | The Week in Review: Dec 21, 2018 – Jan 4, 2019
• 04.01. | Hepatitis B Treatment, Viread, Approved in USA for Children Under 12
• 04.01. | HepCBC Gets Thank-You Letter from Federal Government Agency, CADTH
• 04.01. | Update: Memorial Dinner will Honour Phil Wilkin at Our Place next Thursday, January 10th

2018 (256)

• 21.12. | The Week in Review: Dec 14 – Dec 21, 2018
• 18.12. | Hepatitis C course starting in January
• 18.12. | Cirrhosis of the liver a ‘silent epidemic’ among young adults, women
• 17.12. | NZ: Pharmac to fund new Hep C treatment
• 17.12. | New strains of hepatitis C found in Africa
• 14.12. | The Week in Review: Dec 7 – Dec 14, 2018
• 13.12. | COMMUNITY DINNER January 10th at OUR PLACE in HONOUR of PHIL WILKIN
• 13.12. | Hepatitis C highlights from The Liver Meeting 2018
• 13.12. | Links to the Presentations at the 7th Annual Liver Forum in Vancouver (October 19, 2018)
• 13.12. | Read Joan King’s and Laurel Gloslee’s “Hep C Stories” in new CATIE booklet
• 12.12. | History of Segregated Indian Hospitals in Canada
• 11.12. | Celebrating 25 Years of World AIDS Day in Vancouver!
• 07.12. | The Week in Review: Nov 30 – Dec 7, 2018
• 07.12. | Renally-Impaired Patients with Chronic Hepatitis B Virus Infection Find Success with Low Dose of TDF
• 06.12. | Join Us to Honour & Remember Our Friend Phil Wilkin
• 30.11. | The Week in Review: Nov 23 – Nov 30, 2018
• 30.11. | Phil Wilkin: 1957 – 2018: R.I.P.
• 30.11. | Novel Surrogate End Point Proposed in Hepatocellular Carcinoma
• 23.11. | The Week in Review: Nov 16 – Nov 23, 2018
• 23.11. | Links to a Non-Academic Online Journal and a Blog about Viral Hepatitis
• 23.11. | Elimination of Hepatitis C and the Imperative for Trauma-Informed Care
• 19.11. | Hepatitis C Is Detectable in Rectal and Nasal Fluid
• 19.11. | Targeted Hepatitis C testing misses substantial number of cases in correctional setting
• 16.11. | The Week in Review: Nov 9 – Nov 16, 2018
• 16.11. | Push to test for hepatitis C in Richmond
• 13.11. | HepCBC Reaches Inmates through Info-Fairs at 8 Federal Prisons in BC
• 09.11. | The Week in Review: Nov 2 – Nov 9, 2018
• 09.11. | Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
• 09.11. | High Prevalence of Cirrhosis in Adults With Chronic HBV at a Safety-Net Hospital
• 07.11. | Meet HepCBC’s New Board for 2018-2019
• 02.11. | The Week in Review: Oct 26 – Nov 2, 2018
• 02.11. | Report on The Pacific AIDS Network (PAN) 2018 Fall Conference in Kelowna
• 02.11. | Aging and Viral Hepatitis B and C: A New Study
• 01.11. | Mortality Rates Higher in Acute Hepatitis E Than Hepatitis A
• 31.10. | Potential markers identified for early detection and prevention of liver cancer
• 31.10. | Novel Biomarkers Predict Mortality in Hepatitis B-Associated Liver Failure
• 26.10. | The Week in Review: Oct 19 – Oct 26, 2018
• 26.10. | HepCBC Annual General Meeting INVITATION TO ALL
• 26.10. | 7th Annual Liver Forum 2018 in Vancouver!
• 26.10. | Interleukin IL-22, a new target to inhibit the progression of liver disease
• 25.10. | Does Pharma Try to Influence Patient Advocacy Groups such as HepCBC?
• 19.10. | The Week in Review: Oct 5 – Oct 19, 2018
• 19.10. | Want a Say in the Direction of HepCBC?
• 18.10. | UC researchers recommend universal screening to tackle rise in Hepatitis C
• 18.10. | Does Cannabis Use Reduce Cirrhosis Risk in HCV Patients?
• 15.10. | HepCBC at the Coast Mental Health Clubhouse
• 15.10. | HEP C & PRISONS Webinar NOW AVAILABLE for online viewing!
• 05.10. | The Week in Review: Sep 28 – Oct 5, 2018
• 05.10. | Is hepatitis C virus micro-elimination feasible among prison populations? Let’s look at the world’s first prison to eliminate hepatitis C!
• 03.10. | First Human Case of Rat Strain of Hepatitis E Seen in Hong Kong
• 28.09. | The Week in Review: Sep 21 – Sep 28, 2018
• 28.09. | A Deadline and an Invitation: HepCBC Seeking Board Members, Members, and Volunteers before October 3rd, 2018
• 28.09. | Key Messages from Dr. Julio Montaner at World Hepatitis Day Vancouver 2018
• 28.09. | HepCBC Info Tables Pop Up in Variety of September Venues
• 21.09. | The Week in Review: Sep 14 – Sep 21, 2018
• 15.09. | New Chinese HBV Pamphlets from HepCBC
• 14.09. | The Week in Review: Sep 7 – Sep 14, 2018
• 14.09. | Showcasing HepCBC’s Translation Team
• 14.09. | HepCBC Volunteers Return to the Kitchen Table
• 08.09. | New test aims to help identify thousands in B.C. unknowingly living with hepatitis C
• 07.09. | The Week in Review: Aug 31 – Sep 7, 2018
• 07.09. | London Drugs Launches Potentially Life-Saving Hepatitis C Screening at Pharmacies in BC Lower Mainland
• 05.09. | Hundreds of patients from Stittsville medical centre tested for hepatitis and HIV
• 04.09. | Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine
• 31.08. | Coffee, Pot Linked to Lower Mortality From Hepatitis C
• 24.08. | The Week in Review: July 27 – August 24, 2018
• 22.08. | Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.
• 22.08. | Drop in Aussies seeking hepatitis C cure
• 21.08. | Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 SlideShow: Part 2
• 19.08. | Hindi and Punjabi HBV and HCV Pamphlets Now Available
• 19.08. | FDA OKs First-Line Tx for Unresectable Liver Cancer: First new upfront treatment option in over a decade
• 06.08. | Patients with chronic HBV die at younger age
• 03.08. | New online calculator predicts clinical improvement in liver failure after Hep C treatment
• 31.07. | Serum M2BPGi Reliably Assesses Liver Fibrosis in Chronic Hepatitis B
• 27.07. | The Week in Review: July 20 – July 27, 2018
• 27.07. | HEPCBC Expands Mandate to Cover Hepatitis B and other types of Viral Hepatitis
• 27.07. | OPINION: Nine countries will eliminate hepatitis C by 2030. Why not Canada?
• 26.07. | July 28 World Hepatitis Day Sample Social Media Posts
• 25.07. | BCCDC Grand Rounds for primary care on HCV; MoC credits available
• 25.07. | Vancouver Infectious Diseases Centre: Find 50
• 25.07. | Physician-Treaters in BC for HepB and HepC Updated
• 23.07. | Hepatitis C – The disease with no warning
• 20.07. | The Week in Review: July 6 – July 20, 2018
• 20.07. | Zepatier Plus Sovaldi Beats Hep C in Those With Cirrhosis and Genotype 3
• 17.07. | Dirty Ottawa clinic equipment may have affected 4,600 patients
• 06.07. | The Week in Review: June 29 – July 6, 2018
• 06.07. | Updated and New Materials from HepCBC
• 03.07. | PHAC’s New STBBI “Action Framework”: A commentary
• 29.06. | HepCBC Visit to First Nations Residential School Centre at UBC, April 2018
• 29.06. | HepCBC Federal Prison Outreach, June 18-22
• 29.06. | HepCBC at Snaw-Naw-As Health Fair, April 2018
• 29.06. | HepCBC at CADTH Conference in Halifax, April 2018
• 29.06. | HepCBC at Surrey Water Polo Health Fair, April 21, 2018
• 29.06. | HepCBC at Vancouver East Side Pride, June 23, 2018
• 29.06. | The Week in Review: June 22 – June 29, 2018
• 28.06. | DAA Therapy Highly Efficacious for HCV Treatment in Older Adults
• 28.06. | Boomer Moms At High Risk For Hep C, Says Doctor
• 24.06. | Health unit urges dental patients to get tested after child revealed to have hepatitis C
• 23.06. | NZ: Campaign to be first to wipe out hepatitis C
• 23.06. | Liver highlights from DDW 2018
• 22.06. | The Week in Review: June 15 – June 22, 2018
• 18.06. | Researchers find a promising new approach for treating liver cirrhosis
• 17.06. | All Kids Should Have a Hepatitis B Shot
• 16.06. | Switching to Tenofovir vs Continuing Entecavir in Chronic Hepatitis B
• 15.06. | The Week in Review: June 8 – June 15, 2018
• 15.06. | Canada is facing a tsunami of liver disease and cancer: U of T expert
• 14.06. | Lungs from deceased donors with hepatitis C can be safely transplanted: researchers
• 12.06. | BC Centre for Disease Control Responds to Recent Findings on Hep C
• 12.06. | DAA Therapy Outcomes in HCV-Infected Transplant Candidates After Organ Delisting
• 08.06. | The Week in Review: June 1 – June 8, 2018
• 07.06. | How Do You Die from Hepatitis A?
• 07.06. | U.S.: Half of hepatitis C patients with private insurance denied life-saving drugs
• 04.06. | Findings could lead to treatment of hepatitis B
• 04.06. | New guidelines recommend hepatitis C screening be done for those born between 1945 and 1975
• 01.06. | Addressing Palliative Care in Hepatocellular Carcinoma
• 01.06. | The Week in Review: May 25 – June 1, 2018
• 31.05. | Large Study Confirms DAAs Protect Against HCC When Sustained Viral Response Achieved
• 31.05. | HCV Guidance Updated for Screening and Treating Key Populations
• 31.05. | How Durable Is the Hepatitis B Vaccine?
• 30.05. | When you think having a disease is ‘punishment’ for past behavior
• 30.05. | ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study
• 26.05. | Hepatitis C Virus Infection Linked to Gut Dysbiosis
• 25.05. | The Week in Review: May 18 – May 25, 2018
• 24.05. | Liver Stiffness Measurement as a Potential Screening Tool for Liver-Related Events in HCV
• 22.05. | Hepatitis C Infections Resulting From Medical Treatment Occur Despite Clear Guidelines
• 21.05. | Study finds three major factors for liver cancer
• 18.05. | The Week in Review: May 11 – May 18, 2018
• 16.05. | Promoting Drug Pricing Policy Resources for Patient Groups
• 16.05. | Do fatigue and quality of life improve after hepatitis C is cured?
• 16.05. | Liver disease a growing problem as boomers age
• 16.05. | As HCV Rises Among Pregnant Women, At-Risk Infants Inadequately Screened
• 15.05. | Needle exchanges coming to 2 Canadian prisons
• 15.05. | What it’s like to grow up with a disease that’s kept secret: ‘I felt unclean’
• 11.05. | The Week in Review: April 28 – May 11, 2018
• 10.05. | BRIEF: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B
• 10.05. | This Common Viral Disease Has Plagued Humanity Thousands of Years Longer Than We Thought
• 10.05. | Biologic Psoriasis Therapies Pose Limited Risk for Hepatitis B Reactivation
• 02.05. | Er Nurse Could Have Exposed Thousands of Patients to Hepatitis C Infection, Officials Warn
• 27.04. | The Week in Review: April 20 – April 27, 2018
• 26.04. | Legislation will prohibit payment for blood and plasma collection
• 26.04. | Pilot program connects Vancouver immigrant communities with hepatitis C treatment
• 26.04. | Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation in patients without hepatocellular carcinoma in the USA
• 26.04. | The Sum is More Than the Parts: Effects of HIV and Alcoholism or Hepatitis C on the Brain
• 24.04. | Synthetic cannabinoids and Hepatitis A could be a fatal combination
• 24.04. | NCCN: Screen for Liver Cancer in Patients at Risk
• 23.04. | Metabolic Syndrome Associated With Higher ALT Levels in Chronic Hepatitis B
• 20.04. | The Week in Review: April 13 – April 20, 2018
• 18.04. | Green tea supplements may cause liver damage, warns EU watchdog
• 18.04. | Race May Affect Ability to Achieve SVR in Hepatitis C
• 18.04. | Saskatchewan: Liver screening event looking for undiagnosed hepatitis cases
• 14.04. | Punjab, India: Mass treatment of a population with chronic hepatitis C infection produces high rates of cure
• 13.04. | The Week in Review: April 6 – April 13, 2018
• 12.04. | Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative
• 12.04. | Screening for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis achieving sustained virological response is likely to be cost effective
• 12.04. | 8 reports on liver cancer outcomes with HCV, DAA therapy
• 11.04. | Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind
• 11.04. | Initiative aims to treat Hepatitis C in Alberta patients who also have HIV
• 11.04. | Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation in patients without hepatocellular carcinoma in the USA
• 10.04. | New Guidelines, Expanded Opportunities Mark EASL’s Liver Congress
• 09.04. | Hepatitis B increases mortality risk in patients with acute hepatitis E
• 06.04. | The Week in Review: March 23 – April 6, 2018
• 05.04. | Liver Cancer on the Rise in Backdrop of Undiagnosed Hep C
• 05.04. | EASL releases clinical practice guideline for hepatitis E
• 05.04. | Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
• 01.04. | In worldwide first, Hong Kong hospital probe finds common blood tool infected liver patient with hepatitis C virus
• 29.03. | Hepatitis: India to keep fighting, new test may come handy
• 27.03. | Obesity Linked to Increased Risk of Liver Cancer in Hepatitis B Patients
• 26.03. | Testing for hepatitis C lags with baby boomers despite high infection rate
• 26.03. | Hepatitis B: Four in five infected Britons don’t know they have the virus
• 23.03. | The Week in Review: March 16 – March 23, 2018
• 22.03. | Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 SlideShow
• 21.03. | Novel score predicts DAA benefit in patients with HCV, decompensated cirrhosis
• 18.03. | Herbal assault: liver toxicity of herbal and dietary supplements
• 16.03. | The Week in Review: March 9 – March 16, 2018
• 16.03. | Newly Discovered HCV Subtype is Resistant to Antiviral Treatment
• 15.03. | North Island HepC HepB Roadshow: Days 1 and 2
• 15.03. | Study shows shorter hepatitis C regimen effective in black patients
• 14.03. | Grants Awarded to 13 Canadian Initiatives to Help Advance the Goal of Eliminating Chronic Hepatitis C Infection in High-Risk Populations
• 13.03. | Tattoo and needle programs in prisons would help curb hepatitis: internal memo
• 13.03. | Chronic hepatitis C medication now available for all British Columbians
• 13.03. | Quebec Expands Patient Access to Chronic Hepatitis C Therapies
• 09.03. | Is Hepatitis C Treatment Safe? by Lucinda Porter, RN
• 09.03. | The Week in Review: March 2 – March 9, 2018
• 09.03. | Lack of hep C treatment for N.S. inmates missed opportunity in disease control: advocates
• 08.03. | Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018
• 08.03. | Newer drugs make hepatitis C-positive kidneys safe for transplant
• 07.03. | Tenofovir disoproxil fumarate (TDF) not beneficial for reducing mother-to-child transmission of hepatitis B when added to existing preventatives
• 06.03. | Japan: Couple held over bogus hepatitis C drug served fresh warrant over fake Harvoni tablets
• 05.03. | Ontario: Provincial funding for hepatitis C drugs a game changer, health professionals say
• 05.03. | Managing HBV Infection Following Liver Transplant: Expert Q&A
• 04.03. | Hep C Screening Urged For Boomers, Drug Users, And Immigrants
• 02.03. | 7 reports on liver transplant outcomes in patients with HCV
• 02.03. | The Week in Review: February 23 – March 2, 2018
• 01.03. | USA: The VA Will Eliminate Hepatitis C In Veterans By Year-End
• 01.03. | Alpha Fetoprotein Testing May Detect Liver Cancer Sooner
• 01.03. | Shifting from concern to crisis: 1 in 4 Canadians may be affected by liver disease
• 28.02. | Large Study Confirms DAAs Protect Against HCC When SVR Achieved
• 28.02. | Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan
• 27.02. | Ireland: Six in 10 people infected with hepatitis C undiagnosed
• 27.02. | DAA therapy improves HCV-related liver transplantation outcomes
• 27.02. | Chronic Hepatitis B: Serum ALT Cutoff Value Predictive of Liver-Related Mortality
• 23.02. | The Week in Review: February 16 – February 23, 2018
• 22.02. | Marijuana might save your liver, according to a new study
• 22.02. | Smoking threatens health gains from hepatitis C treatment, US researchers warn
• 21.02. | Ontario removes fibrosis requirement for HCV treatment effective Feb 28th.
• 21.02. | Significant Mortality Benefit Seen With Sustained HCV Virologic Response With DAAs
• 20.02. | Alcohol use disorder compromises benefits of DAA therapy for HCV
• 17.02. | Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict
• 16.02. | The Week in Review: February 9 – February 16, 2018
• 16.02. | Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes
• 14.02. | Evolving Recognition of Chronic Hepatitis C Infection as a Modifiable Risk Factor for CVD
• 14.02. | NZ: Thousands of Hepatitis C sufferers unaware a cure is within reach
• 13.02. | Study reveals the liver’s ‘weak spot’ for hepatitis B virus replication
• 11.02. | Hepatitis C drugs not being accessed by thousands of Australians with the disease
• 09.02. | The Week in Review: February 2 – February 9, 2018
• 09.02. | #EASLmono: Expanding the conversation on hepatitis elimination
• 09.02. | HCV in Older Adults: Effects of Prolonged Infection, Aging-Related Mechanisms, and Treatment
• 09.02. | 7 recent reports on HBV treatment approvals, efficacy
• 07.02. | HCV hospitalizations increasing among baby boomers, men, drug users
• 07.02. | GeoVax and CaroGen to Collaborate On Development of Therapeutic Hepatitis B Vaccine
• 06.02. | CTAC Launches Campaign to End Hepatitis C in Canada
• 06.02. | AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™ – an oral therapy for the treatment of patients with hepatitis C
• 05.02. | Year of the Peer Events: February 27 – March 14
• 05.02. | Attention Hepatitis B (HBV) Patients & Caregivers – Your Help Requested
• 02.02. | The Week in Review: January 26 – February 2, 2018
• 02.02. | HCV Can Reactivate with Treatment of Non-hepatic Cancer
• 01.02. | Compensation – New Update for 86-90 Late Claims
• 01.02. | Last chance for Hepatitis C victims to receive compensation from class action settlement
• 31.01. | Child-Pugh B, C scores predict failure in liver cancer surveillance
• 31.01. | Deaths from liver cancer nearly double since the 1990s, new figures reveal
• 30.01. | SVR for HCV with no advanced liver disease greatly reduces mortality risk
• 29.01. | Viral suppression protects against long-term liver damage caused by older HIV drugs
• 27.01. | CDEC Recommends MAVIRET™ and VOSEVI™ for Reimbursement for Chronic HCV
• 26.01. | The Week in Review: January 19 – January 26, 2018
• 26.01. | Researchers find sofosbuvir effective in treating Zika-infected individuals
• 26.01. | Hepatitis C: ‘6,000 in Wales have virus without knowing’
• 25.01. | Chewing khat leaves increases risk for chronic liver disease
• 25.01. | Treating Insulin Resistance in Hepatitis C-Infected Patients With Diabetes
• 25.01. | Shorter duration of glecaprevir-pibrentasvir effective against hepatitis C virus: The ENDURANCE trials
• 25.01. | Ribavirin Remains Pivotal Component of Hepatitis C Treatment
• 24.01. | Population-based estimate of hepatitis C virus prevalence in Ontario, Canada
• 24.01. | 10 recent HCV reports: SVR outcomes, continued DAA efficacy
• 23.01. | Model predicts progression to acute liver failure in chronic HBV
• 22.01. | Growing Evidence Shows Hepatitis C Intersects With Other Diseases
• 19.01. | The Week in Review: January 12 – January 19, 2018
• 19.01. | Blood test for early detection of 8 cancers looks promising
• 18.01. | Insulin Resistance in HCV May Be Reversed With DAAs
• 18.01. | Men who have sex with men urged to get tested for hepatitis A after another outbreak
• 18.01. | Hepatitis B Vaccination Low Among HIV-Positive Patients
• 18.01. | NASH, HCV cirrhosis predict coronary artery disease in liver transplantation
• 18.01. | Smoking reduces survival after liver cancer diagnosis for people with viral hepatitis
• 12.01. | The Week in Review: January 5 – January 12, 2018
• 11.01. | Officials warn customers of London, Ont., nail salon to get tested for HIV, hepatitis B, C
• 09.01. | Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
• 08.01. | Brief: HCV spread from HIV-positive to HIV-negative men who have sex with men
• 08.01. | Brief: Outcome of HBV and HCV associated HCC occurring after renal transplantation.

2017 (385)

• 29.12. | The Week in Review: December 22 – December 29, 2017
• 22.12. | The Week in Review: December 15 – December 22, 2017
• 22.12. | Is Project ECHO the Telemedicine Model That Healthcare Is Missing?
• 21.12. | Eight Genotypes and 84 Subtypes of HCV
• 19.12. | Should uninfected patients accept hepatitis C-infected livers to reduce waiting time?
• 16.12. | Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults
• 15.12. | The Week in Review: December 8 – December 15, 2017
• 15.12. | 8 updates on liver transplantation outcomes for 2017
• 11.12. | Liver Damage Worse in Women With HBV/HCV Coinfection, Risky Drinking
• 09.12. | Liver cancer incidence after HCV therapy linked to risk factors, not treatment
• 08.12. | The Week in Review: December 1 – December 8, 2017
• 07.12. | URGENT BC Patient and Caregiver Input Request: Vosevi
• 06.12. | ‘I will never forget the day I found out I had hepatitis c’
• 06.12. | A South American amphibian could potentially hold the key in curing cirrhosis
• 04.12. | Elevated Levels of HBV DNA and HBsAg May Increase Liver Cancer Risk
• 04.12. | Association Between HBV, HCV and Age-Related Cataracts
• 04.12. | In Argentina INPI rejected a key patent on Sofosbuvir
• 03.12. | Hep C and me: ‘I was nauseous all the time. I couldn’t gain weight. My skin was itchy and raw’
• 30.11. | McGill study finds people infected with HIV more likely to develop fatty liver
• 24.11. | The Week in Review: November 17 – November 24, 2017
• 21.11. | Should people at low risk for HCV infection be screened for the virus?
• 20.11. | US: ACP and CDC issue recommendations for hepatitis B screening, vaccination, and care
• 17.11. | The Week in Review: November 10 – November 17, 2017
• 16.11. | HCV Clinical Guidelines and Patient Management highlights from The Liver Meeting 2017
• 15.11. | Global Perspectives On Hepatocellular Carcinoma
• 15.11. | Liver test to aid paracetamol overdose treatment
• 14.11. | Nivolumab improves outcomes in liver cancer study
• 13.11. | DAAs produce cure rates in HCV/HIV co-infection similar to monoinfection
• 13.11. | The Hidden Disease of the Middle-Aged
• 11.11. | U.S.: Dynavax Announces FDA Approval of HEPLISAV-B™ for Prevention of Hepatitis B in Adults
• 10.11. | How chronic inflammation tips the balance of immune cells to promote liver cancer
• 10.11. | The Week in Review: November 4 – November 10, 2017
• 09.11. | Singapore’s Restalyst develops new method to improve liver cancer diagnosis
• 08.11. | Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients
• 08.11. | Updated List of Physicians in British Columbia Currently Treating Hepatitis B and/or Hepatitis C
• 07.11. | Curing HCV Yields Long-Term Improvement in Quality of Life
• 07.11. | HCV-related liver disease on the rise in women
• 07.11. | Mongolia’s liver cancer crisis: ‘No other country has a problem like this’
• 05.11. | Benitec and Biotron in the race for $3.5b Hepatitis B market
• 04.11. | Cherokee Nation screens more than 40,000 patients for hepatitis C
• 03.11. | Worldwide 52 million children living with viral hepatitis
• 03.11. | The Week in Review: October 27 – November 4, 2017
• 03.11. | Hepatitis C could be eliminated in Canada, but drug prices, screening barriers stand in the way
• 02.11. | Allicia on the Front Lines
• 01.11. | Elevated HBV Marker Increases Risk for Liver Cirrhosis
• 01.11. | Vermont and North Carolina Remove Restrictions to Access to Treatment on Medicaid
• 31.10. | MSF secures lower price for generic hepatitis C treatment
• 30.10. | Fatty Liver Common After Direct-Acting Antivirals for Hep C
• 30.10. | Curing hepatitis C with DAAs linked to 71% reduction in liver cancer
• 30.10. | Maviret cures most people with HCV genotype 3 and those with cirrhosis
• 27.10. | The Week in Review: October 20 – October 27, 2017
• 27.10. | Patient and Caregiver input is requested by BC Pharmacare on AbbVie’s combo of glecaprevir and pibrentasvir (GP) for Genotypes 1-6
• 27.10. | Liver Meeting 2017: I’m A HCV Patient – Show Me What I Need To Know!
• 23.10. | DAA Era Linked with Better Liver Transplant Outcomes
• 23.10. | Transgene‘s Hepatitis B Vaccine Does the Business at Phase I
• 20.10. | The Week in Review: October 13 – October 20, 2017
• 19.10. | Hepatitis C in pregnancy: screening, treatment, and management
• 18.10. | Hepatitis C and the Rheumatologist: Our Role in the Quest for Global Eradication of HCV
• 17.10. | Cannabis May Be Protective Against Steatosis in Persons Coinfected with HIV-HCV
• 17.10. | SVR reduces hepatic venous pressure gradient, portal hypertension persists
• 17.10. | Liver pressure has ‘come of age,’ aids management of liver disease
• 15.10. | Obesity, hepatitis C epidemics drive ‘alarming’ increase in liver cancer incidence, mortality
• 14.10. | AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017
• 14.10. | Gov. Brown declares state of emergency amid deadly hepatitis A outbreak
• 13.10. | The Week in Review: October 6 – October 13, 2017
• 13.10. | How hepatitis C hides in the body
• 12.10. | Platelet count recovers after SVR in HCV, disrupted by HBV coinfection
• 12.10. | Drug Combo Efficacy Examined for Patients with HCV and Kidney Disease
• 11.10. | Rapid fibrosis progression in large proportion of HIV-positive gay men after acute HCV
• 10.10. | Hospice care may come too late for patients with chronic liver disease
• 10.10. | New York’s Unusual Law Is Boosting Hepatitis C Testing
• 09.10. | Blood test may find liver cancer earlier, improve survival
• 06.10. | Treating Hepatocellular Carcinoma: A Fight Against the Odds
• 06.10. | The Week in Review: September 29 – October 6, 2017
• 05.10. | Liver cancer remains a leading cause of cancer-related mortality worldwide
• 05.10. | Viekira Pak safe for patients with HCV, Child-Pugh A cirrhosis
• 04.10. | AASLD, IDSA update HCV guidance for resistance, new drug approvals
• 04.10. | Vivek Ramaswamy’s Roivant backs Arbutus’ hepatitis B program
• 03.10. | Cancers linked to excess weight make up 40% of all US diagnoses, study finds
• 03.10. | U.S.: Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
• 01.10. | Reactivation Rate of Hepatitis B in Inflammatory Arthritis Tx With DMARDs
• 30.09. | 143,000 First Nations to switch to tailored B.C. Pharmacare plan
• 29.09. | The Week in Review: September 22 – September 29, 2017
• 29.09. | Pacific AIDS Network signs HCV Manifesto, signaling its commitment to greater involvement of persons with hepatitis C in its organization
• 29.09. | Merck discontinues HCV programs
• 28.09. | Canada’s nurses applaud billions in savings found in PBO report on pharmacare
• 28.09. | Liver cancer symptoms: These are the eight signs of the DEADLY condition
• 27.09. | Hepatitis B (HBV) Patients & Caregivers – Your Help Requested re Vemlidy
• 27.09. | Per-SVR (pronounced “Persevere!”) Study is Recruiting Participants
• 25.09. | Three or more cups of coffee daily halves mortality risk in patients with both HIV and HCV
• 25.09. | People of Mexican descent in US have more liver cancer risk factors than those living in Mexico
• 24.09. | HepCBC Info Booth at 55+ Lifestyle “Inspired Senior Living” Show
• 24.09. | HepCBC at CGSNA 2017
• 22.09. | The Week in Review: September 15 – September 22, 2017
• 21.09. | Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
• 20.09. | The Financial Burden of Liver Disease
• 20.09. | Hepatitis Info at DTES Alley Health Fair 2017
• 19.09. | In HBV, high core-related antigen levels predict cirrhosis
• 19.09. | Malaysia Allows Generics for Gilead’s Hepatitis C Drug for Which India Issued Patent
• 19.09. | Restrictions Lifted: All Swiss hepatitis C sufferers can access costly drugs like Harvoni
• 18.09. | S.U.C.C.E.S.S. Chinese Health Fair 2017
• 15.09. | The Week in Review: September 8 – September 15, 2017
• 15.09. | Viral hepatitis kills more people than HIV, malaria or tuberculosis
• 14.09. | President’s Report 2017 – HepCBC – Rosemary Plummer, RN – Sept. 12, 2017, Victoria, BC
• 14.09. | HepCBC at St Michael’s University School Volunteer Fair
• 11.09. | HepCBC’s ANNUAL GENERAL MEETING (AGM)
• 11.09. | Women with HCV face low ovarian reserve, infertility, miscarriage
• 11.09. | How liver cancer develops
• 11.09. | Johnson & Johnson pulls plug on Medivir-Achillion hep C cocktail to focus on hep B
• 10.09. | Recovery Day New Westminster 2017
• 08.09. | The Week in Review: September 1 – September 8, 2017
• 08.09. | She thought her mystery ailment was cancer, but bloodwork revealed a surprise
• 08.09. | HCV treatment found safe and effective in individuals with kidney disease
• 08.09. | Fibrosis Faster Among Men With HCV, Study Finds
• 06.09. | Sharing injection paraphernalia does not lead to HCV transmission
• 06.09. | People Who Use Drugs Require Prioritisation Not Exclusion in Efforts to Eliminate Hepatitis C
• 05.09. | Risk for hepatocellular carcinoma after HCV antiviral therapy with DAAs: case closed?
• 01.09. | The Week in Review: August 25 – September 1, 2017
• 01.09. | Overview: Innovative treatments target liver cancer
• 28.08. | ACG Redefines Normal Range of ALT
• 26.08. | Potluck at Middle Eastern Friendship Centre, Surrey BC
• 25.08. | The Week in Review: August 18 – August 25, 2017
• 22.08. | Public health issues Hep B risk warning
• 20.08. | Major UK Supermarket ‘May Have Infected Thousands With Hepatitis E’ – Updated
• 19.08. | Viral Hepatitis Up to 10 Times More Likely in Indigenous Populations
• 19.08. | Treating HCV in Incarcerated Populations Key to Disease Elimination
• 18.08. | The Week in Review: August 11 – August 18, 2017
• 17.08. | Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection
• 17.08. | AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes
• 15.08. | How Do Direct-Acting Antivirals for Hepatitis C Affect the Risk for Hepatocellular Carcinoma?
• 14.08. | Direct-acting Antivirals Effective in Older Patients with Hepatitis C
• 14.08. | Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV
• 14.08. | Hepatitis C Virus Infection and Cardiovascular Disease Risk
• 11.08. | The Week in Review: August 4 – August 11, 2017
• 11.08. | Melbourne scientists are creating mini-livers in a dish
• 10.08. | Routine hospital tool found to predict poor outcomes after liver transplantation
• 08.08. | UK rations hepatitis B vaccine amid global shortage
• 07.08. | Vancouver PRIDE 2017 Sunset Beach
• 04.08. | Subcirrhotic Liver Stiffness Cuts HCC Risk in Hepatitis B
• 04.08. | The Week in Review: July 28 – August 4, 2017
• 03.08. | U.S.: FDA approves Mavyret for Hepatitis C
• 01.08. | U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
• 31.07. | 2017 Vancouver Eastside PRIDE
• 31.07. | WHO approves generic drug to treat hepatitis C
• 31.07. | WHD 2017 Surrey, BC in Pictures
• 31.07. | WHD 2017 Vancouver, BC in Pictures
• 31.07. | Dramatic budget increase for Hepatitis treatment in federal prisons
• 30.07. | SundanceTV and CBC Team for Tainted Blood Scandal Miniseries ‘Unspeakable’
• 29.07. | Sask. doctor concerned about ‘shockingly low’ number of hepatitis C patients being treated
• 29.07. | Modeling Estimates for HCV Related Disease Projections in British Columbia
• 28.07. | The Week in Review: July 21 – July 28, 2017
• 28.07. | WHD 2017 Victoria, BC in Pictures
• 27.07. | Should we be worried about hepatitis E?
• 26.07. | Opinion: Renew strategy to achieve a hepatitis C free future
• 26.07. | Liver transplant news to know: Complication prediction and more
• 25.07. | Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle
• 24.07. | First Patient Treated In Trial of a Novel Liver Dialysis Device, DIALIVE
• 23.07. | Compound Found in Plums Shown to Inhibit Hepatitis C Virus Entry
• 21.07. | The Week in Review: July 14 – July 21, 2017
• 21.07. | Patient Input Is Requested by CADTH on Gilead’s “pan-genotypic” combo of sofosbuvir+velpatasvir+voxilaprevir (brand name “Vosevi”) for re-treatment of patients with hepatitis C, genotypes 1-6
• 20.07. | 500,000 Malaysian have hepatitis C — they just don’t know it yet
• 20.07. | New, cost effective saliva test that diagnoses liver disease
• 19.07. | Engineered liver tissue expands after transplant
• 18.07. | New animal models for hepatitis C could pave the way for a vaccine
• 18.07. | Know Your Status — Get Tested
• 18.07. | FDA approves Vosevi for Hepatitis C
• 17.07. | Hepatitis C: New Drugs Cure It, but Most People Don’t Know They Have It
• 16.07. | Hepatitis C outbreak spurs closer monitoring of Utah health professionals
• 15.07. | High Risk of Complications Post–Hep C Cure for Those With Advanced Liver Damage
• 14.07. | Liver cancer study gives doctors and patients more info on treatment options
• 14.07. | Liver cancer is spreading with deadly intent
• 14.07. | The Week in Review: July 7 – July 14, 2017
• 14.07. | New measures boost addiction treatment access in Victoria
• 13.07. | Norwegian hepatitis C patients wait for treatment due to medicine monopoly: report
• 12.07. | Raw pork main cause of Hepatitis E infection in EU: official agency
• 12.07. | Comox Valley group shares support, cure info about Hepatitis C
• 11.07. | Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®
• 11.07. | Britain launches public inquiry into historic blood supply scandal
• 10.07. | Looking at the Twin Epidemics of HCV
• 07.07. | The Week in Review: June 30 – July 7, 2017
• 07.07. | Patients with HIV, hepatitis C present unique considerations for cardiologists
• 06.07. | Curing hepatitis C improves diabetes control
• 05.07. | Blood contamination scandal: Families seek justice
• 05.07. | Canada Leads International Indigenous Initiative to Make Progress Towards Global HIV, TB and Hepatitis C Targets
• 05.07. | Chronic Hepatitis C and Chronic Kidney Disease: Advances, Limitations and Unchartered Territories
• 03.07. | Hepatitis C and women of childbearing age
• 02.07. | Hepatitis C: New hope for patients
• 30.06. | Guelph dental practice patients at risk of hep C, hep B, HIV infection
• 30.06. | The Week in Review: June 16 – June 30, 2017
• 29.06. | Study Examines Palliative Care Trends in Patients with End-Stage Liver Disease
• 28.06. | Patients of Hamilton doctor may have been exposed to HIV and hepatitis
• 28.06. | 1,000 Covenant Health patients potentially exposed to hepatitis B and C
• 27.06. | Hep C Experts Condemn Cochrane Review Dissing Direct Antivirals
• 26.06. | Injection drug users at four times higher risk of Hep C than HIV: UNODC
• 26.06. | Swiss hepatitis C sufferers to get full access to expensive drug
• 23.06. | CHMP Backs Two Pan-Genotypic Antivirals for Hep C
• 23.06. | New Zealand: Govt asked to greenlight prison Hep-C testing
• 21.06. | Burlington dental patients told to get tested for hepatitis and HIV
• 19.06. | Gilead Receives Approval in Canada for VEMLIDY™ (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
• 16.06. | The Week in Review: June 9 – June 16, 2017
• 15.06. | MY JOURNEY – 2015, by Brenda Thorne
• 14.06. | Transplanting kidneys with Hepatitis C saves patients’ lives, cures disease
• 13.06. | New Hepatitis C Treatment Option Available for Patients Who Failed DAA Therapy
• 09.06. | The Week in Review: June 2 – June 9, 2017
• 09.06. | The Hepatitis C Trust responds to study on hepatitis C treatment
• 08.06. | Sofosbuvir Reduces Transplant Need and Mortality Rates in Hepatitis C Patients, Study Finds
• 08.06. | Researchers identify how class of drugs blocks Hepatitis C virus replication
• 08.06. | WHO recommends Epclusa, a Hepatitis C Combined Therapy in Just One Pill
• 08.06. | Hep C: Coping and Curing – Book Launch
• 08.06. | No valid evidence $40,000 miracle drug cures hepatitis C – study
• 06.06. | On-the-spot hepatitis test being developed in Swansea
• 02.06. | The Week in Review: May 19 – June 2, 2017
• 01.06. | New Combo Pill Offers Hope to Hepatitis C Patients Who Fail Other Treatment
• 31.05. | GET TESTED: 1 in 30 baby boomers have Hepatitis C, 70 percent are unaware
• 28.05. | Critics push back against hepatitis C screening advice, say boomers should be tested
• 24.05. | Indonesian buyers club helps people obtain generic hepatitis C treatment
• 22.05. | Aussie duo find global consumers for Indian generics
• 22.05. | Gilead warns against Hep C drugs from buyers clubs, says patients may be at risk
• 19.05. | The Week in Review: May 12, 2017 – May 19, 2017
• 19.05. | CDC: National Hepatitis C Testing Day is May 19
• 19.05. | Hepatitis C Virus Reinfection is Uncommon for Those on Opiate Substitution Therapy after Being Cured with DAAs
• 18.05. | Patient and Caregiver input is requested by CADTH on AbbVie’s combo of glecaprevir and pibrentasvir (G/P)
• 16.05. | Man who got hepatitis C, HIV from tainted blood asks PM for compensation
• 15.05. | Help4Hep – BC Helpline Now Online
• 12.05. | The Week in Review: May 5, 2017 – May 12, 2017
• 11.05. | U.S.: CDC – New Hepatitis C Infections Nearly Tripled Over Five Years
• 11.05. | AbbVie’s 8-week hepatitis C drug granted early access in UK
• 10.05. | Women & HCV – Screen & Treat Early / Screen Pregnant Women to Prevent Transmission to Children
• 10.05. | The baby boomers’ stealth killer: hepatitis C
• 09.05. | B.C. developed hepatitis C screening test personalizes treatment for patients
• 09.05. | Just 20% of people living with hep C are aware of their status
• 09.05. | AHC Member Call to Action: MP Engagement
• 08.05. | Georgia Serves as Proving Ground for Experiment to Eradicate Hepatitis C
• 06.05. | Genetic Test Could Predict Transplant Success in People with Hep C, Cirrhosis
• 05.05. | The Week in Review: April 28, 2017 – May 5, 2017
• 03.05. | I-MAK Wins: Gilead Loses Appeal on Sofosbuvir Patent in China
• 03.05. | Louisiana proposes tapping a century-old patent law to cut hepatitis C drug prices
• 02.05. | Lotus Glen is Australia’s first hepatitis C-free prison
• 01.05. | Nova Scotia Lists EPCLUSA™ on Public Drug Plan to Treat All Six Genotypes of Chronic Hepatitis C Infection
• 01.05. | Nova Scotia: New drug will help with hepatitis C treatment
• 30.04. | Response from Dr. Grebely concerning DAAs & HCC
• 28.04. | The Week in Review: April 21, 2017 – April 28, 2017
• 26.04. | First U.S. state-by-state analysis of hepatitis C cases
• 26.04. | Hepatitis C documentary sheds light on best practices
• 25.04. | Dr. Yoshida’s Reply to Recommendations on hepatitis C screening for Adults
• 24.04. | AHC Letter: Baby boomers not included in task force guidelines for hepatitis C screening
• 24.04. | Generic hepatitis C drugs continue to produce high cure rates
• 24.04. | Baby boomers not included in task force guidelines for hepatitis C screening
• 24.04. | AbbVie takes aim at Gilead and BMS with 8-week hep C treatment
• 24.04. | Canadian task force rejects calls for widespread hepatitis C-testing
• 23.04. | MicroRNA-34a as a Therapeutic Target in HCC
• 23.04. | Independent Prognostic Markers of HCC Recurrence Identified
• 23.04. | Higher Risk of HCC Recurrence Observed Following DAA Therapy for Hepatitis C
• 22.04. | New report halves the number of people infected with hepatitis C worldwide
• 22.04. | ILC 2017: Investigational dose of oral interferon-free treatment can cure hepatitis C in children
• 22.04. | Cases of hepatitis B and C hit 325 million: WHO
• 21.04. | The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir
• 21.04. | The Week in Review: April 14, 2017 – April 21, 2017
• 21.04. | Hepatitis C “Greyhound” Roadshow to Interior of BC, Part 3 of 3 (March 17-25)
• 21.04. | Organizations hope better access to meds halts spread of hepatitis C
• 20.04. | ILC 2017: Curing hepatitis C reduces cardiovascular risk
• 20.04. | ILC 2017: European countries restrict access to life-saving treatment for hepatitis C
• 20.04. | Hepatitis C Patients at No Elevated Risk of Developing HCC Following DAA Compared to Interferon
• 19.04. | ILC 2017: Four new EASL clinical practice guidelines on the management of liver diseases presented at The International Liver Congress 2017
• 18.04. | U.S.: Kids With Hepatitis C Get New Drugs And Coverage May Prove Easier Than For Adults
• 10.04. | WHO prequalifies first generic active ingredient for hepatitis C medicines
• 07.04. | The Week in Review: March 31, 2017 – April 7, 2017
• 07.04. | U.S.: FDA approves two hepatitis C drugs for pediatric patients
• 06.04. | Wiping out hepatitis C: Alberta doctor explains access to game-changing drug for patients
• 03.04. | Alberta expands drug coverage for hepatitis C patients
• 02.04. | PCPs can play significant role in patients overcoming hepatitis C
• 02.04. | Italy: Hepatitis C, green light to the purchase of generic drugs abroad
• 31.03. | Scale Up of Hepatitis C Treatment Possible as Brazil Rejects Patent on Key Drug
• 31.03. | The Week in Review: March 24, 2017 – March 31, 2017
• 31.03. | France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment
• 30.03. | New research suggests hepatitis B and C could increase the risk of Parkinson’s disease​
• 29.03. | Saskatchewan expands coverage for 6 hepatitis C drugs
• 28.03. | Patients at Calgary home dental clinic may have been exposed to HIV, hepatitis: AHS
• 28.03. | The 2017 Hepatitis C Community Summit – a key step on the road to elimination
• 27.03. | MSF joins Europe-wide action challenging patent on key hepatitis C drug
• 27.03. | HCV Gene Mutations Present New Challenges for Vaccine Development
• 24.03. | The Week in Review: March 17, 2017 – March 24, 2017
• 24.03. | Selkirk College Student Nurses Bring HEPCBC and ANKORS to Hepatitis C Info Event
• 21.03. | British Columbia lists EPCLUSA™ on public drug plan to treat all six genotypes of chronic hepatitis C infection
• 21.03. | ZEPATIER® now covered in Quebec for the treatment of chronic hepatitis C
• 21.03. | Canada needs Hepatitis C testing strategy, says N.W.T. MP
• 20.03. | New Hepatitis C Drugs Might Eliminate the Disease
• 20.03. | EPCLUSA™, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des médicaments de la RAMQ (Quebec)
• 17.03. | The Week in Review: March 10, 2017 – March 17, 2017
• 17.03. | Rural/Remote/Indigenous Hepatitis C Outreach 2017 – Part 1
• 16.03. | Inappropriate syringe reuse led to hep C transmission in Texas hospital, CDC says
• 15.03. | DAAs Promising for HCV Patients With Hepatocellular Carcinoma
• 15.03. | Hepatitis C mutations ‘outrun’ immune systems, lab study shows
• 14.03. | Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study
• 14.03. | Coverage Denials Eyed in HCV Rx Nonstarts
• 14.03. | Hepatitis C Virus and the Dwindling of Research Funding
• 13.03. | Developing HCV Vaccine May Be Possible by Exposing Virus to Immune System Attack
• 10.03. | The Week in Review: March 3, 2017 – March 10, 2017
• 09.03. | Recent trip to the 2017 Liver Symposium with HepCBC at the Banff Springs Hotel, by Susan Malloch, R.N.
• 09.03. | Studies show hepatitis C test rates low despite effective new treatments
• 08.03. | Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!
• 08.03. | March 6th BCCDC presentation in Prince George, BC
• 08.03. | Report on the CASL/CAHN Conferences 2017, by Rosemary Plummer, President of HepCBC
• 07.03. | HCV in Banff: A report from Del Grimstad, Vice-President of HepCBC, and HepCBC representative to AHC
• 07.03. | London liver specialist urges people to get tested, treated, cured and move on with their lives because new drugs have a 98 per cent cure rate
• 07.03. | BC Centre for Disease Control releases massive report on Hepatitis C
• 05.03. | How new hepatitis C drugs could tackle liver cancer, too
• 03.03. | The Week in Review: Feb 24, 2017 – March 3, 2017
• 03.03. | Centre for Disease Control Releasing Report on Hepatitis C Care in Rural/Remote British Columbia
• 01.03. | Egypt: Prime Pharma aims to treat 100,000 foreign patients of hepatitis C
• 01.03. | Hepatitis C drugs re-energize global fight over patents
• 28.02. | Read the U.S. Official Viral hepatitis ACTION PLAN 2017-2020
• 28.02. | Update from Ontario Ministry of Health on Access to Hepatitis C Medicines: Great News
• 27.02. | Ontario: ‘I hope everybody has access to it’: Province to start paying for hep C drugs
• 27.02. | Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer?
• 24.02. | The Week in Review: Feb 17, 2017 – Feb 24, 2017
• 23.02. | New Update for 86-90 Class Action — Feb 23, 2017
• 22.02. | ‘No One Left Behind!’ — Update from Pacific Hepatitis C Network on Recent PharmaCare Developments
• 22.02. | Ontario and British Columbia expand treatment access to chronic hepatitis C (CHC) patients
• 22.02. | Ontario Becomes First Province To List EPCLUSA™ On Public Drug Plan To Treat All Six Genotypes Of Chronic Hepatitis C Infection
• 21.02. | Deal reduces price of life-saving hepatitis C drugs for Canadians
• 21.02. | More patients to benefit from hepatitis C treatments
• 21.02. | Italian Medicine’s Agency (AIFA) Issues Ultimatum to Gilead
• 21.02. | A Statement from the pan-Canadian Pharmaceutical Alliance
• 20.02. | Aust on target to eliminate hep C by 2026
• 20.02. | HCV Screening Shouldn’t Just Focus on At-Risk Populations
• 20.02. | Wide Use of New HCV Drugs Prevents New Cases — ‘Treatment as prevention’ possible
• 18.02. | HCV, HIV, & Substance Abuse – PLFV Chilliwack Conference
• 17.02. | The Week in Review: Feb 10, 2017 – Feb 17, 2017
• 17.02. | U.S.: Doctors, health officials want broad testing for hepatitis C
• 17.02. | U.S.: Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact
• 16.02. | Cirrhosis Increasing Among Hepatitis C Patients, According to Large US Study
• 16.02. | Women’s Night – Stop HIV and Hepatitis C
• 16.02. | MEN’s NIGHT Purpose Society New Westminster, Feb 15, 2017
• 15.02. | Cost causing Canadians to say no to prescribed drugs
• 14.02. | Hepatitis C Patent Challenges In India, Argentina To Allow Generic Production
• 13.02. | Australia: Murray Bridge trials hepatitis C treatment project
• 13.02. | U.S.: Settlement Over Hepatitis Cure OK’d Despite Challenge From Attorneys General
• 12.02. | Cardiovascular Disease Risk Is Higher for People with Hepatitis C
• 10.02. | The Week in Review: Feb 3, 2017 – Feb 10, 2017
• 10.02. | High Rates of Hepatocellular Carcinoma After Hepatitis C Treatment
• 10.02. | Alcohol Induced Cirrhosis Found Less Likely to Cause Liver Cancer Than Previously Thought Compared to Virally Induced Cirrhosis
• 09.02. | Rates of Hepatitis C Coinfection in Patients With HIV
• 08.02. | Will Hepatitis C Virus Medicaton Costs Drop in the Years Ahead?
• 06.02. | High hepatitis C prevalence seen in Amsterdam PrEP study participants
• 06.02. | Doctors’ Notes: Why Toronto is a liver cancer hot spot
• 04.02. | Surrey PLFV Hep C Conference – Feb 3, 2017
• 04.02. | PACE Hep C Lunch N Learn – Feb 1, 2017
• 03.02. | The Week in Review: Jan 27, 2017 – Feb 3, 2017
• 02.02. | Interplay of Hepatitis C Virus Infection with Liver and Kidney Disease
• 01.02. | Health Canada Grants Priority Review to AbbVie’s Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
• 01.02. | Direct-Acting Antivirals for HCV-Associated Rheumatic Diseases
• 01.02. | Curing hepatitis C reduces the risk of diabetes & kidney failure in HIV/HCV-coinfected people
• 31.01. | Regulus Hep C Drug Stays On Clinical Hold (RGLS)
• 31.01. | Liver cirrhosis and decompensation still on the rise among people with hepatitis C
• 27.01. | The Week in Review: Jan 20, 2017 – Jan 27, 2017
• 27.01. | New: HepCBC Prison Outreach
• 26.01. | Hepatitis C Virus Associated With Increased Risk of Variety of Cancers
• 24.01. | Are New Drugs for Hepatitis C Safe? A Report Raises Concerns — Updated
• 24.01. | Two new hepatitis C therapies fast-tracked in Europe
• 23.01. | Egypt combats hepatitis C epidemic with state-run scheme
• 22.01. | Hepatitis C and President Trump – by Lucinda K. Porter, RN
• 20.01. | The Week in Review: Jan 13, 2017 – Jan 20, 2017
• 20.01. | How the U.S. can beat hepatitis C: Don’t buy the pills, buy the company
• 19.01. | Deal with it: Untold Stories of Hepatitis C in Canada
• 18.01. | Blood victim finally told she is free of Hepatitis C – 29 years after becoming infected
• 18.01. | Strategies to address reimbursement restrictions for Hep C treatment: Lessons from Australia
• 17.01. | Japan: Hepatitis C drug fakes found in Nara drugstore chain
• 17.01. | Clean needle programs too dangerous, federal prison officials tell court
• 13.01. | The Week in Review: Jan 6, 2017 – Jan 13, 2017
• 13.01. | Vancouver’s Info Booth at Oakridge Centre Mall
• 13.01. | U.K.: Funding for development of new strategies to treat and prevent Hepatitis C virus
• 11.01. | Black, Hispanic HCV patients more likely to fail DAA therapy
• 11.01. | January 2017 Hepatitis C Update: Past Economic Loss/Dependent (PELD) Fund
• 09.01. | Ontario agrees to fund Toronto and Ottawa safe injection sites amid opioid crisis
• 09.01. | Antiviral Drug Prevents Recurrence of Hepatitis C in Liver Transplant Patients
• 09.01. | Unit helps South Yorkshire hepatitis C sufferers get crucial diagnosis and reduce risk of life-threatening liver damage
• 09.01. | B.C. won’t cover hepatitis C drug that’s possible cure for woman infected with tainted blood
• 06.01. | The Week in Review: Dec 30, 2016 – Jan 6, 2017
• 05.01. | U.S.: FDA grants priority review to Stivarga for second-line treatment of HCC
• 05.01. | Effect of Sorafenib on Overall Survival Dependent on Viral Status
• 04.01. | Could Hepatitis C Damage Your Kidneys as Well?
• 03.01. | Twenty Percent of New Cancer Treatments Do Not Offer a Clinical Benefit
• 03.01. | $100M cash boost for Ascletis as Chinese hep C race gathers pace
• 02.01. | Natco Pharma launches Hepatitis C drug Velpanat in Nepal

2016 (482)

• 30.12. | The Week in Review: Dec 23 – Dec 30, 2016
• 29.12. | Hundreds of Scots who contracted hepatitis C or HIV through infected NHS blood scandal receive extra cash payouts
• 28.12. | Incidence, Risk factors and Prevention of Hepatitis C Reinfection
• 23.12. | The Week in Review: Dec 16 – Dec 23, 2016
• 23.12. | Broader access to costly Hep C drugs may yield few benefits for Pa. Medicaid, study finds
• 22.12. | Etisalat Egypt will sponsor Prime Pharma’s Tour n’ Cure initiative
• 22.12. | Hepatitis C “effectively eradicated” among Irish haemophilia patients
• 21.12. | Hepatitis C, HIV-Led Treatments Shift Toward Primary Care Physicians and Nurse Practitioners
• 21.12. | Low Innovation in HCV Therapies Means Significant Unmet Need Remains
• 20.12. | Syrian family hopes to get ailing child to Canada
• 19.12. | Diabetes Ups Risk of HCC, Death in Patients With Hepatitis C
• 19.12. | Prison Deaths and Hepatitis C: A Health Crisis Behind Bars
• 19.12. | AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
• 16.12. | Hepatitis C Still Increases Mortality Rate After Being Cured
• 16.12. | The Week in Review: Dec 9 – Dec 16, 2016
• 16.12. | Merck wins $2.54 billion in hepatitis C drug trial against Gilead
• 15.12. | Vermont: Advisory board urges expanded access to hepatitis C drugs
• 15.12. | For the Record: Despite Clinical Benefit, Targeted Therapies May Increase Financial Toxicity in CLL
• 14.12. | NZ: Zepatier Now Approved in New Zealand
• 14.12. | Hepatitis-C Tainted Blood Victims Fight Ottawa for Solution to $220M Fund Shortfall
• 14.12. | New approach to liver transplantation: Using a damaged liver to replace a dying liver
• 14.12. | Longer Treatment Duration Cures More Patients with Hepatitis C Genotype 2 and Cirrhosis
• 14.12. | China: Hepatitis C therapy to be improved
• 13.12. | Hepatitis C and HIV medications can be adversely interacted when used together, URI pharmacy professor reports
• 12.12. | Philpott, Goodale announce changes to laws to make safe injection sites easier to open
• 09.12. | The Week in Review: Dec 2 – Dec 9, 2016
• 09.12. | Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir
• 09.12. | Universal Health Coverage—looking to the future
• 08.12. | Free Online Hepatitis C Program Provides Powerful Resource for Consumers
• 08.12. | NZ: SDHB slated for hep C stand
• 07.12. | Now That We Have a Cure for Hepatitis C, What Are the Next Treatment Challenges?
• 07.12. | US: VA dentist resigns after hundreds possibly infected
• 06.12. | We Have Not Abandoned the Principles or Communities We Serve, Neither Should PHAC
• 05.12. | First WHO prequalified hepatitis C rapid test opens the door to expanded treatment
• 04.12. | Hepatitis C breakthrough drugs cost taxpayers $1bn in four months
• 04.12. | On International Day of Persons with Disabilities, protesters say B.C. isn’t doing enough
• 03.12. | RETREAT Score Highly Predictive of HCC Recurrence Risk After Liver Transplantation
• 02.12. | For Some Vermonters Suffering From Hepatitis C, Life-Saving Cure Is Out Of Reach
• 02.12. | The Week in Review: Nov 25 – Dec 2, 2016
• 02.12. | EU health regulator warns some hep C drugs could reactivate hep B
• 01.12. | Information Update – Direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B
• 30.11. | NZers turn to generic Hepatitis C meds
• 29.11. | Mylan enters MPP agreement over affordable hepatitis C generics
• 29.11. | Hepatitis C Damage Doesn’t Stop at the Liver, Renal Failure Risk Seen
• 28.11. | Breakdown of Hepatitis C Genotype Distribution Around the World
• 28.11. | Medivir announces that Janssen has initiated an open-label phase IIb study of the 3DAA combination of simeprevir, odalasvir and AL-335 (JNJ-4178)
• 28.11. | DAA treatment restricted for Canadian hepatitis C patients
• 28.11. | NZ: New drugs for treating hepatitis C will be available to people living in the Waikato and wider Midland area for free
• 28.11. | Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer
• 25.11. | Hep C drug buyers’ club doctor hits out
• 25.11. | The Week in Review: Nov 18- Nov 25, 2016
• 25.11. | Primary care providers can effectively treat patients with hepatitis C
• 25.11. | Smoke & Mirrors: The Effect of Tobacco Smoking on HCV Disease Progression
• 24.11. | Frequent fliers have same cancer risk as obese people: Jet lag ‘drives up bile acid in the liver – and could be behind global spike in diagnoses’
• 24.11. | Compensation funds for tainted blood victims short more than $220-million
• 23.11. | U.S.: Settlement Reached on Washington State Medicaid Denial of Pricey Hep C Drugs
• 22.11. | Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis.
• 22.11. | Cigarette Smoking, Hepatitis C Virus Synergistic in Raising Liver Cancer Risk
• 22.11. | Smoking With Liver Disease – A No-No
• 22.11. | Cigarette Smoking Behaviors and Beliefs in Persons Living With Hepatitis C.
• 22.11. | Ledipasvir-Sofosbuvir OK for Transplant Recipients With Hepatitis C
• 18.11. | The Week in Review: Nov 11 – Nov 18, 2016
• 17.11. | Hepatitis C virus tricks liver cells to sabotage immune defenses
• 17.11. | AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease
• 16.11. | Rise in known Hepatitis C cases possibly due to improved screening
• 16.11. | A Common Virus Could Help Fight Liver Cancer And Hepatitis C
• 16.11. | Statement by the Honourable Jane Philpott on the HIV and Hepatitis C Community Action Fund
• 15.11. | Liver Damage From Supplements Is on the Rise
• 15.11. | Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites, by Alan Franciscus
• 15.11. | Victoria drug users welcome supervised consumption plan
• 14.11. | US: Large Study Identifies Increase of Cirrhosis in Hepatitis C Patients
• 14.11. | The impact of sustained virological response to HCV infection on long term risk of hepatocellular carcinoma: the BC Hepatitis Testers Cohort
• 13.11. | Is There an Increased Risk of Cancer After Taking Direct-Acting Antiviral Medication?
• 13.11. | Editorial: It’s cheaper to fly to India than treat Hep C in NM
• 13.11. | Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
• 12.11. | AASLD 2016: Efficacy of Antiviral Agents for Hepatitis C in HCC Patients
• 12.11. | AASLD 2016: Cost-Benefit of Treating Hepatitis C in HCC Patients Before Transplant
• 12.11. | US: Half of HCV patients with advanced liver disease receive treatment
• 11.11. | The Week in Review: Nov 4 – Nov 11, 2016
• 11.11. | USA: 3 Years – The Time It Could Take To Cure Nearly Every Veteran With Hepatitis C
• 11.11. | Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C
• 10.11. | Hologic Obtains Canadian Approval for Aptima® Hepatitis C and B Quant Assays
• 10.11. | USA: FDA Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
• 10.11. | Extrahepatic Manifestations of Hepatitis C: Screening and Management: a podcast by Jordan J. Feld, MD, MPH and Joel S. Emery, HBSc, MD
• 10.11. | New Research Project Explores Curing Liver Cancer at the Nano Level
• 09.11. | Should Generic DAAs Be More Widely Imported?
• 09.11. | Probable Drug Interaction Between Warfarin and Hepatitis C Therapy
• 09.11. | High BMI, Type 2 Diabetes Associated With Increased Liver Cancer Risk
• 09.11. | Bayer Seeks FDA Approval For Regorafenib As Liver Cancer Treatment
• 08.11. | Delayed HBV, HCV diagnosis may increase advanced liver disease
• 08.11. | Knowledge for Change: An Introduction to Access to Generic Hepatitis C Medicines
• 07.11. | Cocrystal Announces Positive Interim Data from an Ongoing Phase 1 Study with CC-31244 for the Treatment of Chronic Hepatitis C Infection
• 06.11. | Hepatitis C, HIV Patients Find Cheaper Drugs Via Online Buyers Clubs
• 04.11. | The Week in Review: Oct 28 – Nov 4, 2016
• 04.11. | BC Ministry of Health’s Refusal to Reimburse Critical Drug “Zaxine™” for Hepatic Encephalopathy
• 04.11. | Pan-Genotypic Hep C Drug Epclusa™ Recommended for PharmaCare Coverage by CADTH
• 04.11. | Who sets the maximum price allowed for patent medicines in Canada, including hep C treatments?
• 04.11. | These researchers think they have a solution to the global crisis in drug prices
• 03.11. | DAA Combination Treatment Fast and Effective for Hepatitis C
• 03.11. | Gilead’s hepatitis C freefall just keeps going. What’s the company to do?
• 03.11. | What Are the Out of Pocket Costs for Harvoni, Viekira Pak and Epclusa under Medicare Part D?
• 02.11. | Vietnam vets urged to receive hepatitis C testing
• 01.11. | Acute hepatitis after heavy energy drink use ‘a warning to the consumer,’ liver specialist says
• 01.11. | HCV reinfection common in MSM with HIV
• 01.11. | Recurrent viremia infrequent in hepatitis C
• 31.10. | Two genes linked to increase in immunity to hepatitis C after childbirth, study shows
• 31.10. | Tampa Bay woman with Hepatitis C reduces co-pay for treatments with coupon
• 30.10. | Dating after Hepatitis C: Hope on the horizon for the 1 in 30 boomers estimated to be infected
• 29.10. | Why all those discarded needles are signs of progress for HIV, Hep C in Southern Interior
• 28.10. | Generic hepatitis C drugs purchased online achieve high cure rates
• 28.10. | The Week in Review: Oct 23 – Oct 28, 2016
• 27.10. | Restricted Reimbursement for DAAs Hinders Progress Towards Global Hepatitis C Eradication Goal
• 27.10. | Pharmacist Charged for Hepatitis C Drug Fraud
• 27.10. | Over 1 million treated with highly effective hepatitis C medicines
• 27.10. | Transplant experiment relies on hepatitis C-infected kidneys
• 25.10. | Weighing Longer Lengths of Stay Against Potential Hepatitis C Detection
• 24.10. | Scientists uncover why Hepatitis C virus vaccine has been difficult to make
• 24.10. | AHC Responds to the PHAC Communtiy Action FUND LOI Process
• 23.10. | Announcement: HepCBC Boycotting Pacific AIDS Network (PAN)
• 21.10. | A promising Hep C program seems to be working — and it could be a model for other countries
• 20.10. | Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients
• 18.10. | Coinfection with HIV-Hepatitis C Can Increase Cancer Risk
• 18.10. | Why Doctors Without Borders said no to 1 million free vaccines
• 14.10. | The Week in Review: Oct 8 – Oct 14, 2016
• 14.10. | Canadians Infected by Hepatitis C Have Limited Access to Direct-Acting Antivirals
• 13.10. | U.S.: Prisoners With Hep C Get Cured In Some States But Not Others
• 12.10. | Public Health Agency of Canada Cutting Funding to Canadian AIDS Service Organizations
• 12.10. | Hospitalizations in Immigrants and Nonimmigrants Diagnosed With Chronic Hepatitis C Infection in Québec
• 11.10. | Reducing the duration of hepatitis C therapy may be effective
• 09.10. | Pakistan: Pharma firms’ plea against cut in Hepatitis C drug price dismissed
• 08.10. | Study of liver pathogen in horses could help rein in hepatitis C in humans
• 07.10. | Shedding Light on a Dark Day
• 07.10. | The Week in Review: Sep 30 – Oct 7, 2016
• 06.10. | Plant Extract (Quercetin) Inhibits Hepatitis C, Study Finds
• 05.10. | Study: Modern Hepatitis C Drugs are Very Costly and Unavailable to Many State Prisoners
• 05.10. | European regulator amends some Gilead hep C patent claims
• 05.10. | Hepatitis C: Gilead patent on sofosbuvir partially maintained following MdM patent opposition
• 04.10. | FDA Adds Boxed Warning to Hepatitis C Drugs, Warns of Hepatitis B Reactivation Risk
• 04.10. | UNITAID and FIND launch initiative to improve diagnostics and treatment for hepatitis C
• 04.10. | Merck to Present New Data on ZEPATIER™ (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting® 2016
• 03.10. | U.S.: AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
• 03.10. | Effective antiviral treatment reduces fatigue in people with chronic hepatitis C
• 01.10. | Furor Over Drug Prices Puts Patient Advocacy Groups in Bind
• 30.09. | October 1: A Momentous Day for Many People Living with Hepatitis C in New Zealand
• 30.09. | Dark Day in Canada for Hepatitis C Patient Advocates
• 30.09. | The Week in Review: Sep 23 – 30, 2016
• 29.09. | HCV Infection Increases Extrahepatic Mortality
• 28.09. | Australia leading world in hepatitis C treatment; but disease more prevalent in Aboriginal people
• 27.09. | Hepatitis-C Tainted Blood Victims Demand Equal Treatment
• 26.09. | Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV
• 24.09. | Hep C and the false economy of the health care system: Fiorito
• 23.09. | EASL Releases 2016 HCV Recommendations
• 23.09. | U.S.: Hepatitis C Treatment Panel Calls For Hepatitis B Testing
• 23.09. | Weekly Bull September 23, 2016
• 23.09. | HepCBC Info Booth — 55+ Lifestyle Show Vancouver 2016
• 22.09. | Hep C: Concerns about Thyroid Disease and Interferon Treatment Noted
• 21.09. | Prisons: The Problem and Solution of Hepatitis C?
• 21.09. | Canadian victims of tainted blood seek equal treatment
• 20.09. | New Study: Negotiated Hepatitis C Prescription Drug Costs in United States Often Lower than in Price-Controlled European Countries and Japan
• 19.09. | Philips unveils innovative interventional oncology solution for liver cancer treatment at CIRSE 2016
• 19.09. | Liver cancer risk influenced by blood selenium levels
• 19.09. | Hepatitis C rate increased in Nova Scotia, national rate decreased
• 19.09. | Chinese Health Fair, Burnaby 2016
• 16.09. | Clinical Trial in Canada by Abbvie is Recruiting
• 16.09. | 2016 AGM: Meet the New Board of Directors
• 15.09. | Acetaminophen labels changing to emphasize liver risks
• 14.09. | Woman says she contracted hepatitis C at dentist
• 13.09. | Penn researchers: Hep C drugs make more kidneys safe for transplant
• 13.09. | The lab breakthrough that paved the way for today’s pricey hepatitis C cures
• 13.09. | Inventor of Hepatitis C Cure Wins a Major Prize—and Turns to the Next Battle
• 12.09. | Gilead Again Defends Against Lawsuits Over Patents for Hepatitis C Treatments
• 10.09. | Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV
• 09.09. | The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada
• 09.09. | Federal Judge Finds Violation in Pennslvania’s Refusal to Treat Mumia’s Hep-C
• 09.09. | What Do You Say?
• 07.09. | New research supports hep C treatment for people who use drugs
• 06.09. | Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine
• 06.09. | U.S.: VA estimates 107,000 vets have undiagnosed or untreated hepatitis C
• 05.09. | A Regimen for HCV-Infected Patients Who Fail Direct-Acting Antiviral Therapy
• 03.09. | All You Need to Know: September’s Crucial Verdict on the Sofosbuvir Patent Saga
• 02.09. | Hep C testing drive after blood contamination report
• 31.08. | Exploring Treatment Failure Among Hepatitis C Patients
• 31.08. | Even Light Drinking Spikes Cancer Risk in Hepatitis C-Related Cirrhosis
• 24.08. | REQUEST FOR PATIENT and CAREGIVER INPUT: Gilead’s EPCLUSA
• 24.08. | HIV not a risk factor for fibrosis progression in people with hepatitis C
• 24.08. | Tainted-blood victims to receive more compensation after court rulings
• 20.08. | Compensation Update: Judgments in Provincial Courts – ALL THREE DECISIONS ON ONE PAGE! (Ontario, BC, and Quebec)
• 19.08. | Get tested for Hep C, Georgetown woman urges
• 18.08. | Georgia Launches New National Strategy to Eliminate Hepatitis C
• 18.08. | Victims of Canada’s tainted blood scandal to share $207M compensation fund surplus
• 18.08. | U.S.: Hillary Clinton calls out drug maker Gilead over price of hepatitis C pills
• 18.08. | US: Judge allows public employees access to pricey hepatitis C drugs
• 17.08. | Colorado board recommends expanded coverage for hepatitis C drug
• 15.08. | Australia: Get tested, get treated, Hep C researchers urge
• 15.08. | Hepatitis C in CKD: Challenges and Opportunities
• 14.08. | Taiwan: Oral hepatitis C treatment closer to full NHI coverage
• 13.08. | Thousands likely undiagnosed with hepatitis C
• 11.08. | U.S.: VA Extends New Hepatitis C Drugs to All Veterans in Its Health System
• 09.08. | The ‘R’ Word: The Sad Reality of Relapse
• 09.08. | Viral Mechanisms Provide New Hepatitis C Drug Target
• 08.08. | Highly curative hep C treatment safe and effective for drug users
• 08.08. | The use of generic medications for hepatitis C
• 04.08. | Lisle man unknowingly lived with Hepatitis C for 28 years
• 03.08. | Healthy livers grown from rejected donor organs in transplant breakthrough
• 03.08. | Annual event spreads word on Hep C myths
• 02.08. | Brazil: Testing and Free treatment help more people with chronic hepatitis C to be cured
• 02.08. | Opinion: Canada’s hepatitis C screening policies are failing everyone, especially baby boomers
• 29.07. | Woman ‘humiliated’ after clinic refuses to do allergy test because she had hepatitis C
• 28.07. | WHD 2016 Surrey in Pictures
• 28.07. | WHD Vancouver in Pictures
• 28.07. | WHD Victoria in Pictures
• 28.07. | World Hepatitis Day is July 28th. Read the selected articles from Gastroenterology & Hepatology for free until Sept 1!
• 28.07. | Opinion: Can we eliminate hepatitis?
• 27.07. | Screen baby boomers to better protect Canadians from hep C, say Edmonton virologists
• 27.07. | ‘I thought my life was over’: World Hepatitis Day sparks awareness in Saskatoon
• 27.07. | Children Exposed To Hepatitis C May Be Missing Out On Treatment
• 27.07. | Hep C: an unnecessary epidemic
• 26.07. | Why baby boomers need a hepatitis C screening
• 25.07. | AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
• 25.07. | WHD 2016: BC Proclamations
• 25.07. | “Miraculous,” new treatment for Hep C
• 24.07. | Advocates push need for hepatitis C screening
• 22.07. | U.S.: Vertical HCV Transmission on the Rise
• 22.07. | Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer
• 21.07. | New Poll Finds 64 Percent of Global Doctors Believe New Hepatitis C Drugs Are Worth the Cost
• 21.07. | Not Getting the Message: Too Many Canadians Born Between 1945-1975 Unaware of Their Increased Risk of Undiagnosed Hepatitis C
• 20.07. | Action Hepatitis Canada World Hepatitis Day 2016 Advocacy Toolkit
• 18.07. | Hundreds of patients at risk of Hepatitis B and C after improper sterilization at north Edmonton clinic
• 18.07. | Egypt: State council rules for free treatment of Hepatitis C patients
• 15.07. | “Cure” for hepatitis C carries heavy price tag
• 14.07. | ‘Miracle’ hepatitis C drug remains largely inaccessible: Elevate NWO
• 14.07. | Decisive Action Needed to Increase Patient Access to Hepatitis C Treatment
• 13.07. | Hepatitis C cure approved by Health Canada
• 13.07. | Taxpayers Funded A Lifesaving Drug And Guess What Happened Next
• 12.07. | DAAs Eradicate Hepatitis C, But Not the Risk for Liver Cancer
• 11.07. | Judges ask Ottawa to compensate victims of tainted-blood scandal
• 08.07. | European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
• 07.07. | Viral hepatitis ‘kills as many as Aids or TB’
• 06.07. | Direct-Acting Antiviral Treatment Linked with HCC Recurrence for Patients with Hepatitis C Infection
• 06.07. | Tainted Blood Hearings Done – No Resolution Yet
• 06.07. | India may soon get Epclusa treatment for Hepatitis C
• 05.07. | How Gilead’s New Hepatitis C Virus Combination Stacks Up to the Competition
• 05.07. | U.S.: Medicaid, Private Insurers Begin To Lift Curbs On Pricey Hepatitis C Drugs
• 03.07. | Fibrosis in HCV genotype 3 progresses with age
• 30.06. | U.S.: MassHealth to pay for hepatitis C drugs for all infected members
• 29.06. | Bayer’s Regorafenib Significantly Improves Overall Survival in Patients with Unresectable Liver Cancer
• 28.06. | A Comprehensive And Fair Solution To The Price Of Medicines
• 28.06. | U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
• 27.06. | Unrestricted Medicaid Access to Novel Hepatitis C Therapies May Reduce Overall Costs
• 27.06. | Regulus Reports Clinical Hold of RG-101
• 27.06. | Our Call to Arms: HCV Kills More Than Any Other Infectious Disease
• 21.06. | Cheryl Reitz’s verbatim testimony at today’s Blood Scandal Compensation Fund hearing
• 21.06. | Victims of Canada’s tainted blood scandal fighting for $236M ‘surplus’ in compensation fund
• 21.06. | Newer tests could cut hep C diagnosis steps in half
• 20.06. | Updated–Hep C tainted blood victims, federal government argue in court over $250M fund
• 20.06. | Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus
• 18.06. | India: Punjab: Government launches special fund for free treatment of Hepatitis C
• 17.06. | Kiwis chase overseas drugs to help battle Hepatitis C
• 17.06. | Liberals refuse top up fund for those affected by tainted-blood scandal
• 16.06. | Canada takes a stand against Viral Hepatitis
• 15.06. | Ottawa trying to recoup surplus funds earmarked for tainted-blood victims
• 15.06. | Hepatitis C: Once the viral infection has healed, high-risk portal vein hypertension also diminishes
• 15.06. | Canada’s hepatitis C – tainted blood victims are getting RE-VICTIMIZED.
• 14.06. | London, Ontario declares ‘health emergency’ over rise in HIV and hepatitis C
• 14.06. | Ireland: Additional 1,500 people to be given life-saving hepatitis C treatment
• 13.06. | Taiwan: Experts urge action to cut ‘mad levels’ of hepatitis C
• 10.06. | Testing finds thousands of patients with hepatitis C in one Alabama emergency room
• 09.06. | Race does not impact early mortality among patients with chronic HCV
• 09.06. | U.S.: Foundation calls PA’s treatment of hepatitis C troubling
• 09.06. | U.S.: Delaware lifts restrictions on who can qualify for hepatitis C treatment
• 09.06. | U.S.: Denying Medicaid Patients Access to Hep C Treatments is Wrong and Illegal
• 09.06. | Northern Health seeks to boost HIV, hepatitis C services
• 07.06. | Judge nixes Merck’s $200M hep C patent win, citing ‘fabricated’ testimony, ‘pervasive’ misconduct
• 07.06. | Australia shows an alternative to rationing hepatitis C treatment
• 06.06. | Hepatitis C and Zika Virus, by Lucinda Porter
• 06.06. | U.S.: New Medi-Cal rules ease access to hepatitis C drugs
• 06.06. | U.S.: Deadly Hep C Going Untreated in Native Communities
• 05.06. | New drugs could eliminate need for liver transplants in some patients
• 02.06. | Hepatitis C Spread by Alternative Therapy
• 02.06. | Nearly 250 Organizations across Canada Call for Prison-Based Needle and Syringe Programs
• 02.06. | France to provide universal access to hepatitis C treatment
• 01.06. | Florida changes hep C drug policy for Medicaid after lawsuit
• 31.05. | Large global range of prices for hepatitis C medicines raises concerns about affordability
• 31.05. | Alert: Fake Hepatitis C Medicines
• 28.05. | Governments on track to eliminate viral hepatitis by 2030
• 27.05. | Washington state told to lift restrictions on hepatitis C medicines
• 27.05. | Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union
• 27.05. | Study Finds Patients with Hepatitis C Have Higher Hospitalization Rate
• 27.05. | Tainted Blood Compensation Fund Update – ACTION Requested!
• 27.05. | Viral suppression restores life expectancy in hepatitis C-related cirrhosis
• 27.05. | European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
• 27.05. | hepc.bull May 2016 Now Online!
• 26.05. | Babies among hep C victims of heroin epidemic
• 25.05. | Novel Drug Combo Succeeds Against Multiple HCV Genotypes
• 25.05. | Revolutionary hepatitis C drugs leave public health systems reeling
• 24.05. | Health Canada Approves DAKLINZA™ (daclatasvir) for Difficult-to-Treat Hepatitis C Patient Populations
• 23.05. | State official: Hepatitis C flying under the radar but numbers rising
• 20.05. | Patient input is requested by BCPharmaCare for BMS’s Sunvepra™ (asunaprevir)
• 19.05. | A better liver through chemistry: Pauktuutit takes aim at hepatitis C
• 18.05. | U.S.: New York State AG settles with CDPHP over hepatitis C coverage
• 18.05. | U.S.: Ninety percent of Colorado residents with hepatitis C going untreated
• 18.05. | Could hepatitis C treatments help prevent virus transmission?
• 17.05. | Positive Living North launches Hep C testing campaign during Hepatitis Awareness month
• 17.05. | Opinion: It’s now possible to envision a future without Hepatitis C
• 14.05. | Activists take India’s patent office to court over Gilead’s hepatitis C drug
• 12.05. | New Hep C Recommendations Target Unique Populations
• 10.05. | What price a miracle? Limited access to hepatitis-C drug sparks debate
• 10.05. | Update: India Patent Office approves Gilead’s hepatitis C drug patent
• 10.05. | Alcohol accelerates liver damage in people living with hepatitis C
• 10.05. | New NCCIH Clinical Digest: Hepatitis C and Dietary Supplements
• 10.05. | HCV-related cirrhosis prevalence increases over time
• 09.05. | Hepatitis C outbreak in Jerusalem possibly linked to scanner
• 09.05. | Woman survives more than 30 years with hepatitis C
• 09.05. | Gilead gets patent for Hepatitis C drug Sovaldi
• 09.05. | Pay now or pay more later: Treating hepatitis C
• 09.05. | Treating patients for hepatitis C could reduce the need for liver transplants
• 08.05. | Only 8 of 3,487 Tennessee inmates with hepatitis C receiving treatment
• 08.05. | NZ: Hepatitis C drug funding could happen from July
• 07.05. | Hepatitis C Now Leading Infectious Disease Killer in U.S.
• 07.05. | Sky-high price of hepatitis C drug produces profits for lawmakers
• 07.05. | Hepatitis C ‘Get Tested’ Ads on Buses across Northern BC
• 03.05. | First Nations communities complete hepatitis C training
• 03.05. | A Hepatitis C Screening Protocol That Works
• 03.05. | Japan’s PMDA reviews hep B risk link to hep C therapies
• 03.05. | First Canadian Study Demonstrates Potential to Remove Patients from Active Liver Transplant List After Curing Hepatitis C
• 29.04. | hepc.bull April 2016 Now Online!
• 28.04. | Rare disease gene has a key role in chronic hepatitis C infection
• 27.04. | U.S.: New York Medicaid to cover hepatitis C treatment
• 26.04. | Canadian Blood Services CEO must resign: OPSEU
• 26.04. | U.S.: New York Insurers to Change Coverage of Hepatitis C Drugs
• 25.04. | Cognitive function associated with increased microglia activation in patients with HCV
• 25.04. | Successful treatment for hepatitis C reduces risk of liver cancer later in veterans
• 22.04. | Patient Input Is Requested by CADTH on Gilead’s Combo of Sofosbuvir and Velpatasvir for Genotypes 1, 3 and 4
• 22.04. | China Eases Path for Foreign Drugmakers’ Hepatitis C Treatments
• 21.04. | Video: The cost of curing Hepatitis C
• 21.04. | AIDS expert to head $5-million research efforts on hepatitis C
• 21.04. | Abbotsford man cured of hepatitis C by new, expensive treatment
• 20.04. | U.S.: Prescriber Restrictions Hurt Hepatitis C Patients, AAFP Argues
• 18.04. | AbbVie hepatitis C combo shows high cure rates
• 16.04. | Generic Hepatitis C Drugs as Effective as Pricey Brand Names: Study
• 16.04. | Burnaby woman’s hepatitis C is gone, but better health remains elusive
• 15.04. | Hepatitis C treatment may not be enough to stop the progress of advanced liver disease, or reduce liver transplant need
• 15.04. | New triple drug combination shows promise in hepatitis C infected patients
• 15.04. | Hep C ‘viral time bomb’ can be defused, says doctor who set up real-life Dallas Buyers Club operation
• 15.04. | EU extends safety review of chronic Hep C treatments
• 14.04. | High SVR rates found with AbbVie’s Viekirax and Exviera for hepatitis C – regardless of variants
• 14.04. | Quest Launches New Hepatitis C Virus Test Capabilities for Recently FDA-approved Antiviral Therapies
• 14.04. | US: AG sues CDPHP for delaying hepatitis C coverage
• 14.04. | Hep C Liver Transplant May Work for Those Infected
• 13.04. | Current hepatitis C virus testing guidelines miss too many cases, study suggest
• 13.04. | Hepatitis C treatment for under $300 coming soon
• 13.04. | People with hepatitis C are two to five times more likely to develop certain head and neck cancers
• 13.04. | High rate of cancer recurrence found in certain hepatitis C patients
• 13.04. | CROI 2016: Primary Care Providers Can Successfully Treat People with Hepatitis C
• 13.04. | Hepatitis B and C could be eliminated as public health problems in US
• 13.04. | Patient input is requested by BCPharmaCare for Merck’s MK2: Zepatier (grazoprevir / elbasvir)
• 12.04. | UK: MP to bring hepatitis C sufferer’s cash fight to Parliament
• 06.04. | Baby boomers often unaware they need hepatitis C screening
• 06.04. | Hepatitis C in Limelight Again at Liver Congress
• 05.04. | Editorial: Hep C epidemic can be stemmed
• 04.04. | The Low Cost of Universal Access
• 04.04. | Utah Health Department investigation finds 16 cases of hepatitis C
• 02.04. | Hepatitis C sufferer warns ‘hundreds of thousands will die’ if India changes patent law in trade deal
• 31.03. | North American Hepatitis C Epidemic Peaked Around 1950, 15 Years Earlier Than Previous Estimates
• 31.03. | Hepatitis C in baby boomers unrelated to risky behaviour, researchers say
• 31.03. | Hepatitis C virus uses Netrin-1 to hijack host cells
• 31.03. | Study: Czech incidence of hepatitis C eight times higher than previously believed
• 30.03. | Liberal Government’s Quarter-Billion Dollar Broken Promise That No One Talks (or Knows) About
• 30.03. | Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016
• 30.03. | New Travel Horizons: Hepatitis C Tourism From China
• 29.03. | Hepatitis C Deaths Rising in US
• 27.03. | Drug subsidies could eliminate Hepatitis C in Australia within a decade, experts say
• 24.03. | UPDATE 1-Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute
• 22.03. | More cost-effective cure for hepatitis C may be close
• 22.03. | Merck Wins Hepatitis C Drug Patent Claim Against Gilead
• 21.03. | U.S.: Michigan Medicaid now approving coverage of popular Hepatitis-C drug
• 21.03. | U.S.: FDA approves expanded use of Roche hepatitis C virus RNA test as aid in diagnosis
• 19.03. | Regulus to Present New RG-101 Data at The International Liver Congress™ 2016 (ILC 2016)
• 19.03. | NZ: NZ scientist proves new drug to be a ‘silver bullet’ for Hepatitis C – so why isn’t it available to other Kiwis?
• 18.03. | EMA to Review New Hep C Drugs for Possible Hep B Reactivation
• 18.03. | Scotland: Payment rise for hepatitis C infected blood victims
• 18.03. | U.S.: Hepatitis C-infected kidneys to be used in transplants in clinical trial
• 17.03. | U.S.: Rhode Island Hep C Complications Projected to Continue
• 17.03. | Biotron Phase 2 Hepatitis C Trial Success
• 16.03. | Opioid Substitutes Do Not Impede Hep C Combo Drugs
• 16.03. | Devising a Strategy to Control the HCV Epidemic in British Columbia, Canada
• 16.03. | U.S.: Casting a Wider Net for Cases of Hepatitis C, the ‘Baby Boomer’s Virus’
• 15.03. | Hep C Treatments Can Cause Adverse Effects in Older Patients
• 14.03. | Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals
• 10.03. | “Irresponsible” not to adopt national hepatitis plan
• 10.03. | U.S.: Gilead spars with Merck over hepatitis C $1,000-a-pill royalties
• 09.03. | U.S.: VA expands hepatitis C treatment to all patients with the virus
• 08.03. | ‘Zovaldi’ For Zika? Hepatitis C Technology to the Rescue
• 08.03. | Help shape effective responses to the spread of hepatitis C virus
• 07.03. | U.S: Good Days Announces New Alliance with Help-4-Hep to Provide Holistic Support for People with Hepatitis C
• 07.03. | Counterfeit Versions of Gilead’s Blockbuster Hepatitis C Drug Found in Israel
• 06.03. | Modified protein reverses cirrhosis in lab rats
• 05.03. | Australia: Discounted drugs end the buyers’ club era for Hepatitis C sufferers
• 04.03. | Scientists may have found cancer’s ‘Achilles heel’
• 03.03. | U.S.: NY attorney general to investigate insurers over hepatitis C drugs
• 01.03. | Point of view: Living no more with Hepatitis C
• 29.02. | U.S.: Senator ‘appalled’ by hospitals’ objection to providing Hep C test
• 29.02. | Australia: Hep C cures now as cheap as $6.20
• 26.02. | China: Executives sacked for hepatitis C negligence
• 26.02. | Update on TT-034 Hepatitis C Clinical Trial
• 26.02. | Patent Challenge Hearing on Gilead Hepatitis C Drug Sofosbuvir Starts in India
• 26.02. | Australia: Hep C horror at Fiona Stanley
• 26.02. | Healthcare worker who put 8,000 patients at risk of hepatitis C is named as a surgeon who caught the virus during an operation and DIED from it in 2012
• 25.02. | ‘Climbing for Carleen:’ Colorado Springs family makes mountain treks to raise awareness of hepatitis C
• 24.02. | Hologic Hepatitis C Viral Load Test Fares Well in German Validation
• 22.02. | New recommendations in the updated WHO guidelines for the screening, care and treatment of persons with chronic hepatitis C infection
• 22.02. | Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure Rates Among HCV Genotype 1b Patients
• 22.02. | Indian scientists develop Hepatitis C vaccine
• 19.02. | Kyrgyzstan’s Long Fight for Generic Drugs Is Finally Paying Off
• 19.02. | Direct-acting antivirals reduce cryoglobulinemia in hepatitis C
• 18.02. | New DAA Hepatitis C Drugs – BBC Newsnight – 17th February 2016
• 18.02. | Clinical Trials in Canada: Updated February 18, 2016
• 18.02. | U.S.: Lawsuit targets Medicaid policy that limits spendy hepatitis C drugs
• 17.02. | Kim Goldberg cured of Hepatitis C Speaks Up
• 17.02. | Hepatitis C-Free Europe is Possible by 2030
• 17.02. | Regulus hep C combo drug effective in mid-stage study
• 16.02. | U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
• 15.02. | Hepatitis C patient: ‘…Price gouging was a crime, or isn’t it?’
• 15.02. | U.S.: More bad news for hep C drug pricing
• 14.02. | Vietnam vets blame ‘jet guns’ for their hepatitis C
• 12.02. | How the Cherokee Nation plans to reverse the ‘silent epidemic’ of hepatitis C
• 11.02. | Are States Obligated to Provide Expensive Hepatitis C Drugs?
• 09.02. | Merck Receives Approval of ZEPATIER™ (elbasvir/grazoprevir) in Canada for the Treatment of Chronic Hepatitis C for Patients with Genotype 1, 3, or 4 Infection Following Priority Review
• 08.02. | mapCrowd Launch
• 08.02. | Lucinda Porter honored for hep C education
• 08.02. | FDA Approves Expanded Use of Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
• 07.02. | Good Samaritan Helps Woman Denied Insurance Coverage Receive Lifesaving Hepatitis C Drug
• 06.02. | Merck ushers in price war for hepatitis C medicines with new drug
• 05.02. | hepVoice – new monthly magazine from the World Hepatitis Alliance
• 05.02. | ReDEMPTION eTrials Now Open
• 05.02. | Hep C nurse excited about new drug
• 03.02. | Prison needle programs touted to reduce HIV and Hep C
• 03.02. | U.S.: Lawmaker: Costly hepatitis C drug “a slap in the face to the veterans”
• 03.02. | U.S.: Lawsuits claim insurers unfairly refuse pricey hepatitis C drugs
• 02.02. | Hepatitis-C survivor lives to help, gets 400 treated
• 31.01. | NZ: Kiwis join Australian hepatitis C buyers’ club
• 31.01. | Lawrie McFarlane: Concerted effort needed to limit drug prices
• 30.01. | Undetectable – My Hep C Story: A Book of Poems by Kim Goldberg
• 30.01. | U.S.: Clinicians encouraged to screen for hepatitis C based on birth year
• 29.01. | Merck launches hepatitis C drug price war
• 29.01. | European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C
• 28.01. | FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4
• 28.01. | Hepatitis C Reported at 19 Dialysis Clinics: CDC
• 28.01. | Something is Definitely Wrong: California Doles Out Millions to Insurers for Hepatitis C Drugs
• 27.01. | Why is Gilead charging VA $40,000 for drug?
• 27.01. | The Prevalence of Cirrhosis in Patients with Hepatitis C Is Growing
• 27.01. | Pamela Anderson Cured of Hepatitis C But Others Wait for Miracle Drug
• 27.01. | Massachusetts is investigating high cost of hepatitis C drug
• 26.01. | Most Children Born to Hepatitis C-Positive Mothers Don’t Get Tested
• 25.01. | Pricing of Hepatitis C Medicines in Canada: AHC Position Statement
• 24.01. | Hepatitis C Can Be Cured in Canada, But This Life-Saving Drug Is Outrageously Expensive
• 23.01. | Jacques Chambers, CLU: RIP
• 23.01. | World Hepatitis Day 2015 Summary Report released
• 22.01. | Cardiovascular disease risk is higher for people with hepatitis C
• 22.01. | Zepatier Approved in Canada
• 21.01. | Australia: Top End doctors, recovered sufferers overjoyed by hepatitis C funding changes set for March
• 21.01. | Clinical Trials in Canada: Updated January 21, 2016
• 21.01. | Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population
• 21.01. | Natco Pharma signs agreement for manufacture and sale of hepatitis C drug
• 20.01. | The History of Hepatitis C and New Drugs To Help Treat It
• 20.01. | Hepatitis C patients with certain gene type more prone to diabetes: Study
• 20.01. | Sex, drugs, rock ’n’ roll – then hepatitis C treatment
• 20.01. | The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir
• 19.01. | Challenging hepatitis C-infected liver transplant patients
• 18.01. | Kiwi hepatitis C patients getting treatment from Australian drug buyers club
• 16.01. | Desi generics firms pave way for cheaper hepatitis C drug
• 15.01. | India: Hepatitis-C cases up, Rohtak docs blame barbers, quacks
• 14.01. | Prisons face hep C-treatment funding crisis – CMAJ
• 12.01. | AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen
• 12.01. | Pricey hepatitis C drugs threaten health care system
• 11.01. | Medical Tourism in India: How Does It Work?
• 11.01. | Canadian Govt. Recommends Treatment for All
• 06.01. | Action Hepatitis Canada Age Cohort Testing Position Statement
• 05.01. | Inside the hepatitis C virus is a promising antiviral
• 04.01. | Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir
• 04.01. | The drug that costs more than $1200, and sells for $5 in India
• 02.01. | Why Hepatitis C Is Often Called ‘The Silent Killer’: Natalie Cole Obit

2015 (89)

• 30.12. | Research shows hepatitis C is associated with increased risk of heart disease
• 26.12. | India: New, better, cheap Hep C drugs to help patients, attract foreigners
• 26.12. | New Zealand: Hep C patient goes offshore for cure
• 26.12. | India: Govt adds cancer, HIV, Hepatitis C to list of essential medicines
• 23.12. | Hepatitis C Linked to Parkinson’s Disease
• 22.12. | New compound triggers immune response to range of RNA viruses, including Ebola and hep C
• 22.12. | U.S.: State declares public health emergency for Monroe County amid hepatitis C epidemic
• 21.12. | **HepCBC HOLIDAY HOURS**
• 19.12. | Christmas comes early for Australians living with hepatitis C
• 19.12. | Australia: Turnbull government to spend $1 billion on hepatitis C ‘miracle cures’ for all
• 18.12. | Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure
• 17.12. | Hepatitis C prevention, control efforts should focus on incarcerated individuals
• 16.12. | Curing Hepatitis C, in an Experiment the Size of Egypt
• 14.12. | Young hep C patient gets new lease on life (USA)
• 12.12. | Seoul Viosys UV LEDs Zaps Hepatitis C Viruses in Korea
• 12.12. | Hep C cure for a high cost
• 11.12. | Abbott (ABT), UCSF Announce Discovery of New Hepatitis C-Related Human Virus
• 11.12. | Hepatitis C Virus Infection Associated with Rheumatoid Arthritis
• 08.12. | Clinical Trials in Canada for Hepatitis C–Updated December 9, 2015
• 02.12. | Hep C could be next target on Vancouver’s Downtown Eastside
• 02.12. | Maker of $1,000 hepatitis C pill put profit before patients: U.S. Senate
• 01.12. | hepc.bull for December 1, 2015 Now Online
• 30.11. | Combination therapy successfully treats hepatitis C in patients with advanced liver disease
• 30.11. | Real life Dallas Buyers Club operation helps hepatitis C patients with free drugs
• 30.11. | New Bus Ad Campaign in the Fraser Valley
• 25.11. | Scientists homing in on new hepatitis C vaccine
• 24.11. | Liver fibrosis improves after successful treatment for hepatitis C
• 24.11. | AbbVie’s TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection
• 23.11. | Expensive drugs that cure hepatitis C are worth the cost, even at early stages of liver fibrosis
• 23.11. | Bristol-Myers signs deal with U.N. group for generic hepatitis C drug (Daklinza)
• 19.11. | New AbbVie hepatitis C combination cures 93%-97% with genotype 3
• 18.11. | Liver damage underestimated in hepatitis C patients
• 18.11. | At Least 2 Cups Of Coffee A Day May Reduce Impact Of Liver Disease: Australian Researchers
• 16.11. | AASLD 2015: Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3
• 16.11. | AASLD 2015: New AbbVie hepatitis C pan-genotypic combination cures 97% – 100% in early study
• 16.11. | AASLD 2015: Large Cure Rate for HCV May Have a Significant Impact on the Transplant Wait List
• 16.11. | Simple drug combo can cure hepatitis C in 3 months, study says
• 15.11. | AASLD 2015: The Risk of Developing Liver Cancer Even After Being Cured from Hepatitis C
• 14.11. | Hepatitis C: an Effective Regimen for Genotype 3
• 14.11. | One-step test for hepatitis C virus infection developed by UC Irvine Health researchers
• 12.11. | U.S. FDA approves Gilead’s hepatitis C drug for expanded use
• 10.11. | Malta: President presents €1.2 million worth of Hepatitis C medication to government
• 10.11. | Information Update – Risk of Serious Liver Injury associated with Hepatitis C Treatments: Holkira Pak and Technivie
• 06.11. | AASLD 2015 Update: Hepatitis C Still Focus of Liver Meeting
• 06.11. | U.S.: Federal Officials Warn States on Hepatitis C Drug Restrictions
• 06.11. | MPP announces expansion of mandate to hepatitis C and TB medicines
• 04.11. | Gilead’s Sovaldi Tied to Slow Heartbeat in Hepatitis C Patients
• 04.11. | Bradyarrhythmias Associated with Sofosbuvir Treatment
• 04.11. | New Syringe Design Not Particularly Effective at Curbing Spread of Hepatitis C Virus
• 03.11. | Hepatitis C patients who use drugs need multidisciplinary treatment: B.C. study
• 02.11. | New drugs bring new hope to hepatitis C patients
• 02.11. | Health-care workers at heightened risk of hepatitis C
• 31.10. | Federal Inmates Treated for Hep C Drop 29%
• 29.10. | Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
• 22.10. | FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
• 07.10. | Patient Input Requested for Merck Interferon-Free Combo
• 01.10. | Decision about New Hepatic Encephalopathy Drug Urged by HepCBC
• 18.09. | Couldn’t Attend World Hepatitis Summit? View All Presentations Here!
• 12.09. | Aboriginal and Prisoner HCV Drug Coverage for HOLKIRA PAK™
• 06.09. | View all hepatitis C drug Patient Group input from HepCBC
• 31.08. | Patient Input Requested for AbbVie 2D-GT4 Combo
• 30.08. | HepCBC at World Hepatitis Summit in Glasgow, Scotland!
• 20.08. | Daclatasvir coming to a pharmacy near you soon?
• 20.08. | Summer of Interferon-free Hepatitis C Drug Approvals?
• 12.08. | New Activity: HCV-Infected Members of 1986-1990 Class Action Suit
• 03.08. | Bus Ad Campaign in 7 BC Cities urges Hep C Testing of Baby Boomers
• 03.08. | Municipal Leaders get tested for hep C on North Vancouver Island
• 03.08. | Dr. Evan Adams Gets Tested for Hepatitis C
• 03.08. | Loss of HepCBC Board Member Allen McCulloch
• 02.08. | MP Elizabeth May publicly tested for hepatitis C
• 01.08. | World Hepatitis Day 2015 Victoria, BC
• 30.07. | World Hepatitis Day Vancouver 2015
• 11.06. | Cdn Minister of Health replies to HepCBC request for Testing Guidelines release
• 26.05. | Baby Boomer HCV Testing Advocated by BC Legislators in a Big Way!
• 19.05. | Middle-Income Countries consider voiding hepatitis C drug patents
• 18.05. | All MLAs in British Columbia invited to do hepatitis C test May 25 in Victoria
• 15.05. | BC Legislator questions Health Minister about hepatitis C treatment, testing, and education
• 26.04. | REQUEST: Patient input for BC Pharmacare RE: HOLKIRA PAK™
• 24.04. | Hepatitis C Elimination Experiment Launched in Georgia
• 17.04. | MP Health Critic Murray Rankin Gets Tested for Hepatitis C
• 07.04. | REQUEST personal input for Patient Group Submission: HOLKIRA PAK
• 26.03. | URGENT WARNING: Heart meds and sofosbuvir (SOVALDI or HARVONI)
• 26.03. | Updated: HepCBC Patient Group Submissions to CADTH and BC Pharmacare
• 23.03. | Updated: HARVONI & SOVALDI now covered by BC PHARMACARE!!
• 17.03. | Peppermint Patti’s FAQs version 10.1 just released – download free!
• 01.02. | REQUEST Patient input for eltrombopag (REVOLADE) for LOW PLATELETS
• 31.01. | URGENT REQUEST patient input into INTERFERON & RIBAVIRIN-FREE 2-drug combo by BMS
• 28.01. | Cdn HIV/AIDS Legal Network signs HCV Manifesto
• 13.01. | Price of AbbVie Holkira Pak™ hepatitis C treatment in Canada

2014 (50)

• 23.12. | HEALTH CANADA APPROVES AbbVie Interferon-Free HCV Combo
• 22.12. | AbbVie’s 3D Combo now offered in USA at discount via Express Scripts
• 25.11. | Why CADTH needs Patient Group Input from HepCBC
• 25.11. | What price is a life in Australia, China, Egypt, Canada?
• 16.11. | Hepatitis C Vaccine being developed by GlaxoSmithKline
• 14.11. | URGENT REQUEST for patient input into INTERFERON-FREE HCV 3-drug combo by AbbVie
• 13.11. | Simeprevir: two nods from Sask. & Health Canada
• 13.11. | Sign TORONTO DECLARATION on VIRAL HEPATITIS!
• 12.11. | Allison Crowe brings TIDINGS CONCERT to Sidney Nov. 29th, benefit for HepCBC & Artemis Place!
• 11.11. | Hepatitis C Online Memorial Honours Canadians who Died,1996-present
• 01.11. | Bristol-Myers Squibb’s “Stand-Alone” marketing of daclatasvir worldwide refreshing change
• 29.10. | SIMEPREVIR (GALEXOS) now covered by BC PharmaCare!
• 29.10. | HepCBC releases all of its Patient Group Reviews since 2011
• 17.10. | NOC granted to Canada’s first “interferon-free” combo, sofosbuvir/ledipasvir!
• 10.10. | First interferon-free combo approved by USA’s FDA today!
• 09.10. | In Praise of Stand-Alone HCV Drugs
• 15.09. | Sofosbuvir & Ledipasvir price pact for low income countries announced by Gilead
• 10.09. | Articles on hepatitis C drug SOVALDI international pricing, distribution
• 10.09. | Baby Boomer HCV Info video from USA Centre for Disease Control
• 09.09. | PDF of WEBINAR about SOFOSBUVIR and LEDIPASVIR COMBO – Dr. Paul Marotta, Sept. 8, 2014
• 02.09. | 86-90 Class Action Settlement GOOD NEWS about SOVALDI treatment
• 31.08. | URGENT REQUEST for patient input into INTERFERON-FREE HCV drug combo: sofosbuvir+ledipasvir
• 18.08. | PHOTOS: World Hepatitis Day Vancouver 2014
• 02.08. | Sign HCV MANIFESTO online to support TREATMENT ACCESS and FIGHT STIGMA!
• 24.07. | Review new drugs for LOW PLATELETS and HEPATIC ENCEPHALOPATHY
• 24.07. | International HCV drug pricing policies under fire: Australia
• 23.07. | WORLD HEPATITIS DAY ADS now online in Vancouver
• 04.07. | SOVALDI Webinar slides – Link to Dr Ramji July 3 presentation
• 03.07. | CADTH simeprevir (GALEXOS) news!
• 02.07. | SOVALDI: Request personal input into Patient Group Submission
• 30.06. | Sign-in info for FREE SOVALDI webinar July 3, noon
• 27.06. | SOVALDI (sofosbuvir) WEBINAR July 3, noon (PST) with Dr. Alnoor Ramji: FREE, public invited
• 10.06. | US Prisoners get sofosbuvir-simeprevir with new Guidelines
• 05.06. | CADTH Therapeutic Review Input NEWS!
• 04.06. | New COMBO hepatitis C treatment from AbbVie – new factsheet
• 04.06. | Sofosbuvir and Ledipasvir, a new COMBO Hepatitis C treatment
• 03.06. | Simeprevir (GALEXOS) now covered in Quebec as well!
• 02.06. | QUEBEC approves SOVALDI for Hepatitis C (genotypes 1 or 4 only)
• 02.06. | World Health Organization VIRAL HEPATITIS Resolution passes
• 31.05. | Add Hepatitis C to Global Fund? ADD YOUR VOICE!
• 27.05. | New Analysis of Burden of Untreated Hepatitis C in Canada
• 22.05. | DEAL WITH IT! The trailer. Watch film Tues, May 27, Victoria, BC
• 14.05. | PATIENTS, CAREGIVERS: HepCBC NEEDS YOUR INPUT RE: SIMEPREVIR
• 08.03. | Liver Cancer Meeting – Link to Slideshows
• 04.03. | 6 Bright New Posters Released by HepCBC for Outreach into Northern & Remote Communities
• 28.02. | Updates to Canadian sofosbuvir pricing and CADTH queuing schedule
• 28.02. | 22 hepatitis C research videos from Canadian Symposium on HCV, Feb. 7, 2014 in Toronto
• 28.02. | Fighting to make HCV treatment affordable for 170 million people
• 01.02. | Sign HCV Manifesto Online!
• 16.01. | Two National Health Organizations Sign HCV Manifesto!

2013 (25)

• 18.12. | HepCBC VP Blasts MP for Spreading Misinformation about Hepatitis C
• 16.12. | SOVALDI™ (sofosbuvir) approved by Health Canada
• 12.12. | Help transplant patients with a Holiday Hamper from Happy Liver Society!
• 11.12. | AbbVie`s new all-oral, 12-week Hepatitis C treatment cure rate 96% for Genotype 1
• 07.12. | Sofosbuvir (Sovaldi) Approved in USA
• 20.11. | GALEXOS™ (simeprevir) approved by Health Canada
• 18.11. | More Canadian Liver Specialists Stress Urgency of 1-time-only Baby-Boomer Testing for Hepatitis C
• 05.11. | BLOOM CLINIC of Ontario signs HCV MANIFESTO
• 31.10. | ANKORS first Institutional Signer of HCV Manifesto; Congratulations!!
• 28.10. | HCV Manifesto Collecting Signatures of Support from Organizations and Individuals
• 25.10. | Speech to CATIE 2013 Focuses on Unmet Needs of HCV+ Population
• 24.10. | EXCELLENT and CURRENT Hepatitis C Information Guide – THANKS, Boerhinger-Ingelheim!
• 02.10. | URGENT REQUEST FOR YOUR INPUT into a new HCV drug, SOFOSBUVIR
• 23.09. | Looming Hepatitis C Crisis among Un-tested, Un-treated Baby Boomers – Dr. Morris Sherman warns PHAC
• 08.09. | Liver Cancer: All you need to know
• 27.08. | Vancouver volunteers needed to support Liver Transplant patients from outside city
• 23.08. | URGENT REQUEST FOR YOUR INPUT into a new HCV drug, SIMEPREVIR
• 21.08. | B.C. HEPATITIS C LIVER TRANSPLANT PATIENTS FROM OUTSIDE VANCOUVER FACE ADDITIONAL HURDLES
• 14.08. | Ken Thomson of ANKORS & PHCN in Kootenay Region of BC – Sad goodbye
• 23.07. | HEP C RE-DEFINED! a great new resource from Boerhinger-Ingelheim
• 20.07. | WORLD HEPATITIS DAY 2013-British Columbia!
• 20.07. | FREE: Most Current Statistics, Research, and Data about Hepatitis in Canada
• 06.07. | HELP, I need a support team in Vancouver before I can qualify for a transplant!
• 24.06. | Hepatitis C Virus: Is the End in Sight?
• 16.06. | Hepatology 2013 Textbook Free Download

2012 (14)

• 19.12. | Vertex telaprevir (Incivik®) fatalities heighten concern over skin reactions
• 13.12. | Fibroscan update – New machine already installed in Victoria
• 07.12. | HCV+ Baby Boomers with HCC increasing demand for Liver Transplant; may force changes in treatment plans
• 24.11. | Promacta (eltrombopag) approved by FDA for LOW PLATELETS now preventing HCV treatment
• 23.11. | HepCBC benefit “TIDINGS Concert” 2012 – Allison Crowe
• 13.11. | Vancouver Island getting FibroScan Machine in early 2013
• 08.11. | Drug interactions between HCV treatment drugs and other drugs
• 08.11. | View our new HepCBC Liver Warriors VIDEO!
• 08.11. | Difficult Issues now Coming into Focus within HCV+ Community
• 05.11. | Take a Moment to Honour our Friend, Jade Hood
• 05.11. | Welcome to HepCBC’s New Blog!
• 07.08. | PACE (Providing Alternatives Counselling & Education Society) HCV COOKBOOK “A Taste of this Life”
• 07.08. | Untitled poem, by Dianne Scott
• 07.08. | Through HCV treatment many times